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Anaplastic large cell lymphoma represents about 10-15% of pediatric 
lymphomas and has an aggressive clinical course with frequent relapse.  The 
majority of these tumors are characterized by translocations involving the ALK gene.  
The most common is the chromosomal translocation t(2;5)(p23;q35), which is the 
driving oncogenic mutation in these tumors.  The consequence of the translocation 
is the in the expression of a constitutively active tyrosine kinase, the NPM-ALK 
fusion protein.  While significant progress has been made in deciphering the 
signaling mechanisms induced by NPM-ALK, a comprehensive understanding of 
how NPM-ALK induces cell proliferation and survival is lacking.  This level of 
understanding is essential for the development of novel therapeutics to treat patients 
with ALCL and other ALK driven neoplasms.  The aim of this study is to utilize 
unbiased screening approaches to identify novel mediators of NPM-ALK signaling, 
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 NPM-ALK is a fusion tyrosine kinase that drives oncogenesis in a subset of 
anaplastic large cell lymphoma.  Based on the role of NPM-ALK in cancer initiation 
and progression, we pursued a mass spectrometry-based phosphoproteomic 
approach aimed at the unbiased identification of novel mediators of NPM-ALK 
signaling.  The analysis of cell lines under differing NPM-ALK activation conditions 
revealed a significant number of proteins that regulate cellular metabolism to be 
affected by NPM-ALK signaling.  We therefore, pursued an untargeted metabolomic 
screen aimed at the identification of specific metabolites and metabolic pathways 
that are regulated by NPM-ALK.  This analysis revealed significant alterations in 
pathways implicated in the Warburg effect and biomass production, including 
glycolysis, the pentose phosphate pathway, pyrimidine metabolism, etc.  Metabolic 
flux analysis revealed an NPM-ALK-driven up-regulation of these pathways and 
down-regulation of energy production.  We hypothesized that PKM2 and GSK3β, 
both identified in the phosphoproteomic study, mediate the metabolic changes.  
Biochemical studies revealed that NPM-ALK directly phosphorylated PKM2, 
decreasing its enzymatic activity and driving a metabolic shift away from energy 
production and toward biomass production.  Chemical activation of PKM2 or 
expression of a mutant PKM2 resulted in a reversal of this metabolic shift and 
decreased tumorigenesis.  The phosphoproteomic analysis identified another 
xv 
 
candidate mediator of NPM-ALK signaling, GSK3β.  Through the PI3K/AKT 
pathway, NPM-ALK regulated pS9-GSK3β, inhibited its activity and provided 
proteasomal protection for Mcl-1, CDC25A and GYS.  This pathway increased 
proliferation and survival, while increasing glycogen production as a form of 
metabolic regulation.  Studies described in this dissertation globally characterize the 
ALK driven phosphoproteome and metabolome while providing mechanistic 
discoveries of two novel NPM-ALK driven pathways.  This work provides significant 
advances to our understanding of oncogenesis and will lead to advances in targeted 










Anaplastic Lymphoma Kinase 
Structure 
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) in the 
insulin receptor subfamily1,2.  The full length protein contains 1620 amino acids and 
most closely resembles the leukocyte tyrosine kinase (LTK).  The two proteins share 
57% amino acid identity and 71% similarity over their overlapping sequences with 
initial characterization of ALK revealing a putative transmembrane domain and an 
extracellular domain.  The initial translation of this 177 kDa polypeptide undergoes 
N-glycosylation and results in a 200 kDa mature protein that is expressed on the cell 
surface that is capable of being tyrosine phosphorylated1.  The extracellular domain 
(ECD) of ALK contains (from N-terminus to C-terminus) a signaling sequence, a 
MAM (meprin, A5 protein and receptor protein tyrosine phosphatase mu) domain 
containing putative pleiotrophin binding sites, an LDLa (low-density lipoprotein class 
A) motif, another MAM domain as well as a glycine-rich domain adjacent to the 
transmembrane domain (Figure 1.1)3,4.  ALK contains a protein tyrosine kinase 
(PTK) domain with identifiable ATP binding sites and putative binding sites for IRS1, 
SHC, PI3K and PLCγ spread throughout the intercellular domain (ICD)4.  The 
presence of the LDLa domain within the ECD supports the role of ALK as a receptor 
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for ligand signaling as these domains are common among cell surface receptors and 
have been shown to be critical in ligand binding5-7. 
 
 The ALK kinase domain consists of amino acids 1116-1392 and shows 
significant differences in sequence alignments as compared to other members of the 
RTK family of proteins8.  The activation loop (A-loop) of ALK contains the same 3 
tyrosine motif (YXXXYY) as seen in other RTK proteins of the same subfamily such 
as insulin receptor kinase (IRK).  This A-loop is responsible for autophosphorylation 
and activation of the kinase, however the 3 amino acids separating first and second 
tyrosine residues differ significantly from other members of this family.  Specifically, 
IRK contains a YETDYY motif while ALK contains YRASYY.  This internal triplet has 
been shown to confer recognition and specificity for autophosphorylation as a 
peptide containing the IRK A-loop cannot be phosphorylated by ALK unless the 
Figure 1.1:  Anaplastic Lymphoma Kinase domain structure.  ALK is a Receptor tyrosine 
kinase.  The extracellular domain contains two MAM (meprin, A5 protein and receptor 
protein tyrosine phosphatase mu) domains with putative pleiotrophin binding sites, an 
LDLa (low-density lipoprotein class A) motif, and a glycine-rich domain adjacent to the 
transmembrane domain.  The intracellular domain contains the protein tyrosine kinase 
domain which is responsible for the propagation of downstream signaling events.  The 




triplet is mutated to match that of ALK8.  Mutational analysis of the 3 tyrosine 
residues on the ALK A-loop revealed that the first residue is necessary for 
autophosphorylation and subsequent functional activity9.  Phosphorylation of these 
A-loop tyrosine residues is necessary for the phosphorylation of 8 additional tyrosine 
residues located throughout the ICD, the activation of downstream signaling 
mechanisms and the oncogenic potential of the kinase10.  Crystal structure analysis 
of the ALK catalytic domain has validated the mutational studies of the A-loop 
function as well as provided structural insight to the observed substrate specificity of 
ALK11. 
ALK Ligands 
The natural ligand activating ALK signaling has been a relatively contested 
issue within the literature.  Studies in the Drosophila homologue of mammalian ALK 
(dALK) have identified Jelly Belly (Jeb) as capable of binding to and activating the 
RTK.  Jeb is a secreted LDL receptor repeat protein that is necessary for normal 
development of the visceral mesoderm12. The resulting binding of Jeb to dALK has 
been shown to control normal muscle development in Drosophila and mediate the 
physiological role of Jeb13,14.  However, no known homologue to Jeb exists in 
vertebrates and the Drosophila Jeb is incapable of activating mouse ALK15.  In 
mammalian cells, pleiotrophin (PTN) and midkine (MK) proteins have been shown to 
bind to the ECD of ALK and activate its downstream signaling pathways3,16-18.  PTN 
and MK are both heparin binding growth factors that share about 50% amino acid 
identity 19.  The role of PTN and MK as ligands to ALK is still under debate as 
several groups have presented conflicting data about the ability for these proteins to 
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activate ALK signaling.  These groups were unable to achieve phosphorylation or 
activation of ALK with PTN or MK20-24.   
Several groups have published data providing additional evidence regarding 
ALK and its ligand function.  Prior to the characterization of PTN and MK as potential 
ligands, Iwahara et al. reported the presence of an epidermal growth factor (EGF)-
like domain in the ECD of ALK2.  They suggest that this may serve as an internal 
ligand and facilitate receptor dimerization or cell-cell interactions.  However, 
empirical evidence for these hypotheses has yet to be presented.  Perez-Pinera et 
al. provided a potential explanation for the discrepancy of PTN and MK as an ALK 
ligand25.  Here, the role of PTN in ALK activation was shown to be indirect.  PTN can 
bind and activate the receptor protein tyrosine phosphatase (RPTP) β/δ and its 
downstream signaling pathway.  This results in inhibition of the phosphatase that 
inactivates ALK, leading toward more activation of the receptor.  Another report 
suggests that ALK serves as a dependence receptor26,27.  ALK receptor induces 
apoptosis when expressed in Jurkat cells in the absence of ligation.  While, PTN 
failed to cause ALK activation, the group showed that a monoclonal antibody 
capable of activating ALK induced an anti-apoptotic phenotype in these cells.  These 
data suggest that cells expressing the ALK receptor are addicted to ALK ligand 







Normal expression of wildtype ALK is extremely restricted and is limited to the 
central nervous system including the thalamus, mid-brain, olfactory bulb and 
ganglia2,28.  ALK expression is seen most predominantly in the neurons with 
additional expression in glial cells and endothelial cells of the central nervous system 
(CNS).  Additionally, ALK expression is strong in these tissues as early as E15 of 
mouse development but quickly decreases following birth.  At 3 weeks of age, ALK 
expression reaches a minimum level but is still detectable through adulthood.  These 
data suggest that wildtype ALK plays an important role in the development and 
function of the central nervous system. 
Drosophila ALK 
Several groups have focused their efforts on understanding the role of ALK in 
Drosophila in order to decipher its physiological role.  Drosophila ALK was first 
characterized by Loren et al. where they identified dALK as a novel receptor tyrosine 
kinase4.  They reported expression of the protein in developing CNS as well as 
additional expression in the developing visceral mesoderm.  The mesoderm 
expression of ALK was coincident with phospho-ERK expression.  To further this 
notion, the same group later showed that loss of function mutations in dALK resulted 
in defects in gut development suggesting a role for ALK in the visceral mesoderm 
during embryogenesis29.  More recently, a series of reports have emerged 
suggesting additional roles for ALK in developmental and behavioral control.  Cheng 
et al. reported that ALK is necessary for protecting neuroblast growth during nutrient 
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restriction by signaling through PI3K30.  These data illustrate that previously 
unknown mechanisms to protect vital organs during development in the event of 
starvation.  However, this also has implications in human tumor biology as many 
cancers exhibit starvation resistant phenotypes31.  An additional study showed that 
ALK negatively regulates both body size and associative learning in Drosophila 
through the activation of dNf1 (ortholog of the Neurofibromatosis type 1 (NF1) 
disease gene) signaling pathways and inhibition of ALK was shown to rescue the 
dNf1 mutant phenotype32.  Recently, Lasek et al. reported that ALK is associated 
with altered behavior responses to alcohol and showed that mutant flies lacking 
functional dAlk had resistance to the sedative effects of alcohol consumption33.  
While these data were originally discovered in the Drosophila model system, Lasek 
et al. confirmed these results in mice and humans suggesting a role for ALK kinase 
in response to ethanol.  Taken together, these studies support a role for ALK in a 
variety of neurological, developmental and behavioral phenotypes. 
Mouse ALK 
While ALK knockout mice appear to be normal, fertile and viable, several 
behavioral and psychological defects were identified33-35.  Bilsland et al. were the 
first to report phenotypic findings from ALK knockout mice showing the homozygous 
knockout of the ALK kinase domain resulted in increased basal hippocampal 
progenitor cell proliferation and increased dopamine metabolism in the frontal 
cortex34.  While these mice had no developmental or anatomical problems, 
behaviorally, they displayed signs of decreased depression and increased 
performance in hippocampal-dependent tasks.  Recently, additional phenotypes  
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were reported in ALK deficient mice that supports the role for ALK in neurogenesis 
and brain function35.  Here, mutant ALK was associated with reduced neurogenesis 
but increased spatial memory function.  Specifically, ALK mutant mice exhibited 
fewer doublecortin-positive cells (an indirect measure of neurogenesis)36.  
Consistent with their Drosophila studies, Lasek et al. reported that ALK knockout 
mice have altered behavior responses to ethanol including increased ethanol 
consumption and longer sedation times33.  These studies support the role for ALK in 
neural development and behavioral phenotypes. 
ALK as an Oncogene 
While the physiological role of ALK seems to be nuanced by subtle changes 
in brain development and function, the pathologic role of ALK is anything but 
ambiguous.  The ALK gene is frequently involved in chromosomal translocations 
(Table 1.1), mutations and amplifications that are often seen in a variety of 





Anaplastic Large Cell Lymphoma 
The role for ALK in tumorigenesis has been most thoroughly studied in the 
context of anaplastic large cell lymphoma (ALCL).  ALCL is a form of non-Hodgkin 
lymphoma (NHL) initially described by Stein et al. in 198537.  Here, ALCL was 
identified as similar to Hodgkin lymphoma based on the expression of CD30, but 
morphologically different based on the presence of “bizarre” large cells and other 
markers.  Now, these “bizarre” cells are considered to be the hallmark cells of ALCL.  
Table 1.1: Recurrent ALK Translocations in Cancer 
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A comprehensive analysis of the morphologic features of these cells was first 
eloquently described by Benharroch et al. 
“…all cases shared one common feature, notably the presence of a 
population of large cells with a highly characteristic morphology.  The nucleus 
lay eccentrically within these cells and was horseshoe or kidney shaped. In 
most cases, some crown-like nuclei could also be seen. Nucleoli were less 
prominent than in Reed-Sternberg cells and often an eosinophilic region was 
seen near the nucleus, probably representing a prominent Golgi apparatus.”38 
 
ALCL is most often observed in children or young adults, representing 10-30% of all 
pediatric non-Hodgkin lymphoma39,40.  The expression of ALK is a characteristic 
feature in 60-80% of ALCL cases, and this distinction in ALK expression status is 
significant as the ALK-negative cases of ALCL have been shown to have a reduced 
5-year survival rate compared to ALK-positive ALCL41,42.  The expression of ALK is a 
consequence of recurrent chromosomal translocations involving the ALK gene locus.  
The translocation present in about 80% of ALK+ALCL cases determined to be 
t(2;5)(p23;q35)43-46.  The characterization of this chromosomal translocation led to 
the first description of ALK and gave it its namesake47.   
t(2;5) in ALCL 
The chromosomal translocation t(2;5)(p23;q35) is the quintessential genetic 
abnormality resulting in expression of oncogenic ALK. The result of which is the 
fusion of the tyrosine kinase domain of ALK with a portion of nucleophosmin (NPM).  
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NPM is a ubiquitously expressed nucleolar protein that has a variety of cellular 
functions including nuclear shuttling, ribosomal biogenesis and genomic stability48.  
Importantly, NPM contains an oligomerization domain at its N-terminus that remains 
intact following the t(2;5) translocation.  The consequences of this translocation are 
profound, as it results in the loss of the ALK regulatory and promoter regions that 
normally silence ALK expression in lymphocytes and other adult tissues.  Instead, 
the resulting fusion gene (NPM-ALK) is placed under the regulatory control of the 
NPM promoter which is highly active in most cell types including lymphocytes.  
Additionally, the resulting fusion protein, NPM-ALK, has been shown to be capable 
of autophosphorylation and constitutive activation49.  While NPM-ALK expression 
has transformative effects on NIH3T3 cells, deletion of the NPM portion of the fusion 
protein abolishes this capability50. The reason for which is the presence of the 
oligomerization domain of NPM that aides the dimerization of the ALK kinase 
domain, mimicking ligand binding in the native protein.  Finally, the t(2;5) 
translocation results in aberrant localization of ALK because the breakpoint occurs 
just after the transmembrane domain causing the fusion protein to no longer be 
localized in the membrane.  Instead, NPM-ALK can be found in the cytoplasm and 
nucleus49.  Although the nuclear localization signal in NPM is lost as a result of 
t(2;5), NPM-ALK can been seen in the nucleus.  Presumably, this is a result of the 
formation of heterodimers with NPM-ALK and full length NPM.  However, Brischof et 
al. noted that the NPM-ALK dimerization is the key transforming feature of this 




Variant ALK translocations in ALCL 
While the presence of t(2;5) is the most common ALK mutation in ALCL, 
several other translocations involving ALK have been observed.  These additional 
fusion partners include Tropomycin 3 and 4 (TPM3/TPM4)51-53 TRK-fused gene 
(TFG)54,55, clathrin heavy chain-like 1 (CLTCL)56, 5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC)57-59, Non-muscle myosin 
heavy chain (MYH9)60, Moesin (MSN)61,62, and ALK lymphoma oligomerization 
partner on chromosome 17 (ALO17)63.  The common feature that the majority of 
these ALK fusion proteins have in common is their ability to form dimers and thus 
induce constitutive activation of the ALK kinase domain. Specifically, the TPM and 
TFG fusion partners are capable of dimerization through α-coiled-coiled structures 
which could give rise to ALK activation51,55.  Interestingly, unlike NPM, TPM3 and 
TFG are cytoplasmic proteins therefore the TPM3-ALK and TFG-ALK fusion proteins 
are also localized to the cytoplasm.  ATIC-ALK is thought to be activated through a 
similar means of dimerization initiated by the ATIC region of the fusion protein58.  A 
clear case for dimerization in CTCL-ALK is a little less straightforward.  However, 
since CTCL-ALK has been shown to localize in vesicles within ALCL cells, it is likely 
that the fusion protein is binding to clathrin-coated vesicles, thus providing the close 
proximity necessary for activation of ALK56.  While MSN does not appear to have 
oligomerization properties, it does localize to the cell membrane (as does the MSN-
ALK fusion protein).  This co-localization could provide the close proximity similar to 
CTCL-ALK and subsequent ALK activation61.  While MYH9 does contain an 
oligomerization domain, it is lost as a result of the chromosomal translocation.  
12 
 
Functional analysis of the MYH9-ALK fusion protein showed lack of tyrosine kinase 
activity in vitro but appears to be activated in vivo, suggesting the possibility that 
MYH9-ALK is acting in conjunction with other proteins to achieve activation60.   
Inflammatory Myofibroblastic Tumors 
Inflammatory myofibroblastic tumors (IMT) are members of a broad spectrum 
of neoplastic and non-neoplastic entities termed “inflammatory pseudotumors”64.  
These tumors were originally considered a benign postinflammatory condition rather 
than a neoplastic process.  The tumors are most commonly found in children and 
young adults, though all ages are affected.  Although the location of the tumors 
varies greatly, they are most frequently identified as pulmonary, intra-abdominal or 
retroperitoneal in location.  There is a low risk for recurrence and distant metastasis 
of IMTs.  Histologically, the tumors are characterized by spindle cell proliferation in a 
collagenous stroma with prominent infiltration of plasma cells and lymphocytes.  
Importantly, ALK positive staining can be seen in about 50% of cases (ALK+ staining 
is seen mostly in younger patients)65,66.  It was the identification of 2p23 
chromosomal rearrangements and ALK gene expression that helped to reclassify 
these tumors as neoplastic in origin67. 
The first ALK fusion proteins to be discovered in IMTs were the TPM3-ALK 
and TPM4-ALK oncogenes68.  These proteins were found to be constitutively active 
and drove the oncogenic phenotype of IMT.  Since this discovery, a variety of other 
ALK fusion partners have been identified in IMT, several of which are shared with 
ALCL, including ATIC-ALK and CLTC1-ALK69,70.  However, some of the observed 
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ALK rearrangements in IMTs have yet to be identified in ALCL.  These include 
CARS-ALK, RANBP2-ALK, PPFIBP1-ALK, and SEC31L1-ALK63,71-74. 
Non-Small Cell Lung Cancer 
ALK translocations and fusion protein expression have also been identified in 
non-small cell lung cancer (NSCLC).  About 6% of NSCLC patients have shown 
expression of the ALK protein with an increased frequency in non-smokers75,76.  The 
expression of ALK in NSCLC was originally found to be a consequence of the 
chromosomal aberration inv(2)(p21;p23) and the fusion of ALK to echinoderm 
microtubule-associated protein-like 4 (EML4) gene.  Since its original discovery, 
several EML-ALK gene fusion variations have been identified.  At least eleven of 
these share the same portion of ALK, but varying lengths of the EML4 portion75,77-79.  
The common feature between all EML4-ALK variations is the coiled-coil domain at 
the N-terminal region of EML4 that has been shown to be necessary and sufficient 
for the oncogenic capacity of EML4-ALK.  Interestingly, these mutations seem to be 
mutually exclusive from EGFR and KRAS mutations supporting the role of EML4-
ALK as a driving oncogene and ALK+ NSCLC as a distinct clinical entity80.  
Additionally, several other ALK mutations have been identified in NSCLC at a lower 
frequency than EML4-ALK.  These include TGF-ALK, KLC1-ALK (kinesin light chain 
1), KIF5B-ALK (kinesin family member 5B) and PTPN3-ALK (protein tyrosine 
phosphatase, nonreceptor Type 3) suggesting a broader significance for ALK in 
these tumors81-84. 
Diffuse Large B-Cell Lymphoma 
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ALK translocations have also been identified in rare cases of diffuse large B-
cell lymphoma (DLBCL).  This was originally identified in 1997 and represented the 
first case of ALK oncogenic expression outside of ALCL85.  The most common cause 
of ALK expression is the t(2;17)(p23;q23) translocation resulting in the expression of 
CLTC1-ALK86-88.  Since then, other fusion proteins including NPM-ALK, SQSTM1-
ALK (sequestosome 1) and SEC31A-ALK have been identified89-91.  ALK+DLBCL 
represent a distinct subtype of DLBCL with the presence of immunoblastic or 
plasmablastic cells with prominent nucleoli.  These tumors stain positive for CD138, 
CD45, CD4 and EMA while lacking staining for CD3, CD30, and CD5692.  
Interestingly, mouse models of ALK overexpression develop tumors that resemble 
ALK+DLBCL93. 
Neuroblastoma 
The expression of ALK was also identified in neuroblastoma however, the 
expression is not a result of chromosomal translocations94.  Instead, overexpression 
of ALK as a result of copy number variations was identified along with activating 
point mutations95.  It is important to note the extent to which ALK contributes to the 
oncogenesis of these tumors is still under debate.  Compared to cell lines 
expressing NPM-ALK, full length ALK expressing cells show little to no 
phosphorylation of the receptor, leading to the hypothesis that its expression is 
physiologic as opposed to pathologic20.  ALK overexpression in neuroblastoma often 
accompanies amplifications in MYCN and studies suggest cooperation between 
these oncogenes96-98.  In addition to ALK amplification, several activating point 
mutations have been identified that contribute to the oncogenesis of 
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neuroblastoma99-101.  Dozens of point mutations have since been characterized and 
tend to cluster in or near the kinase domain of ALK.  Residues R1275 and F1174 
seem to be hot spots for mutations and correlate with elevated MYCN amplification 
and poor prognosis102.  Furthermore, 2 truncated forms of ALK have recently been 
identified (ALKdelta4-11 and ALKdel2-3) in neuroblastoma that are constitutively 
activated and possess transformative properties103,104. 
Other ALK Expressing Tumors 
Translocations in the ALK gene locus have been identified in rare cases of 
several other cancer types. Colorectal carcinoma (CRC) has been shown to carry 
EML-ALK mutations in 2.4% of cases and recently, a case of C2orf44-ALK was also 
reported in CRC105,106.  Using a phosphoproteomic approach to identify oncogenic 
kinases in ovarian cancer, Ren et al. identified the oncogenic ALK expression in 
about 2% to 4% of ovarian cancers107.  The expression of ALK was identified in two 
contexts; a result of ALK copy number gains in one patient and the FN1-ALK fusion 
protein in another.  A study in renal cell carcinoma (RCC) identified 2 (out of 6) 
patients to contain ALK translocations with the expression of the novel VCL-ALK 
fusion protein108.  Finally, ALK expression was reported in a subset of breast 
cancers, however, it is not clear whether the ALK expression is a result of full length 
ALK or translocations109. 
ALK Signaling 
Mutations in ALK have been shown to drive the initiation and progression of 
the tumors discussed above.  Much effort has therefore been placed on 
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understanding the signaling events that propagate from ALK to elicit this oncogenic 
effect.  While the complex and overlapping signaling networks are still under 
investigation, three major pathways have emerged as the key mechanisms 
mediating ALK induced oncogenesis.   
STAT3 Pathway 
ALK has been shown to phosphorylate and activate the signal transducer and 
activator of transcription 3 (STAT3) through several important studies (Figure 1.2)110-
113.  STAT protein family members are activated by growth factor receptors, cytokine 
receptors and interferon receptors114.  The consequence of the phosphorylation and 
activation of STATs is the dimerization and nuclear translocation of the proteins 
where they act as transcription factors.   
STAT3 signaling has been shown to be critical for ALCL proliferation and 
survival.  STAT3 knockdown and pharmacological inhibition leads to impaired 
tumorigenesis in ALCL mouse models and is required for the transformation of 
mouse embryonic fibroblasts113.  Expression of a dominant negative STAT3 also 
leads to apoptosis and G1 cell cycle arrest112.  Furthermore, phosphorylated STAT3 
has been identified in primary human ALCL tumors along with its nuclear 
translocation110.  More importantly, expression of phosphorylated STAT3 
corresponds with NPM-ALK expression across other lymphoma subtypes. 
While ALK also binds and activates JAK3, the role of JAK3 as a mediator in 
STAT3 activation is unclear.  JAK3 was reported to not be required for STAT3 
activation, yet additional studies report that the inhibition of JAK3 results in 
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decreased STAT3 phosphorylation and subsequent apoptosis110,115,116.  
Furthermore, activation of JAK3 has been seen in human tumors and associates 
with ALK expression117.  Additional investigation is necessary to illuminate the role of 
JAK3 in the NPM-ALK/STAT3 signaling pathway. 
The activation of STAT3 plays an essential role in ALK mediated 
tumorigenesis as seen by in vitro and in vivo models.  Signaling through STAT3 
induces the transcription of numerous genes responsible for increased survival, 
increased proliferation and immune suppression.  Specifically, STAT3 induces 
expression of numerous survival promoting genes including Bcl-2, Bcl-XL, Bcl2A1, 
Survivin, Mcl-1, C/EBPβ110,118-120.  BCL-2 and BCL-XL are anti-apoptotic proteins 
and their increased expression enhances the survival of NPM-ALK expressing 
cells121.  STAT3 also induces the expression of survivin (a member of the inhibitor of 
apoptosis (IAP) family).  Patients with increased survivin levels predicts poor clinical 
outcome suggesting an important role for STAT3/survivin in ALCL 
aggressiveness122.  STAT3 signaling also promotes the expression of numerous pro-
proliferation genes including Cyclins, CD278, c-Myc, Sox2 and C/EBPβ120,123-126.  
CD278 (ICOS) has been shown to be directly regulated by STAT3 signaling125.  In 
fact, STAT3 directly increases CD278 expression in addition to down regulating miR-
219 which selectively inhibits CD278 expression.  NPM-ALK signaling through 
STAT3 also results in expression of the embryonic stem cell transcription factor 
Sox2126.  While expression of Sox2 was seen in most ALCL cells, transcriptional 
activity of Sox2 is only present in a small subset.  This Sox2 expression is important 
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for ALK+ ALCL tumorigenesis and suggests a major role for a subset of ALCL cells 
maintaining a stem cell-like transcriptional program. 
NPM-ALK induced STAT3 activation supports an immunosuppressive 
phenotype that enables tumorigenesis, which is accomplished through the excretion 
of IL-10 and TGF-β as well as the expression of FoxP3 and CD274 (B7-H1)127,128.  
This expression pattern results in a T regulatory (Treg) cell phenotype initiated 
through STAT3 signaling.  The IL-10 excretion limits proliferation of peripheral blood 
mononuclear cells while enhancing the viability of the tumor cells.  CD274 is a ligand 
for PD-1 and inhibits T-cell activation129. 
STAT3 signal has been shown to be substantiated in ALCL through crosstalk 
with other pathways.  The accumulation and transcriptional activation of β-catenin 
has been observed in ALK+ALCL cell lines and tumors130.  STAT3 expression and 
activation is dependent on this β-catenin activity, as this activity points toward the 
activation and cooperation with the WNT signaling pathway.  Other members of this 
pathway, including casein kinase 2α (CK2α) and Disheveled (Dvl-2/3) have been 
shown to regulate ALCL growth131,132.  Interestingly, CKα was shown to regulate the 
serine phosphorylation of NPM-ALK which, in turn, is required for autoactivation of 
NPM-ALK133.  This convoluted feed-forward signaling loop suggests that ALK 
signaling and WNT signaling work together to not only increase proliferation and 
survival, but to further enhance their own signaling cascades. 
NPM-ALK has also been shown to activate STAT5B134.  JAK2 is constitutively 
active in ALCL cells due to the expression of NPM-ALK135.  The activation of JAK2 
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leads to the activation of STAT5B and the subsequent transcriptional activation of 
downstream effectors such as β-casein.  The JAK2/STAT5B signaling pathway has 
been shown to be necessary for ALCL proliferation and survival through JAK2 
inhibition (AG490) and expression of dominant-negative STAT5B mutant.  
Conversely, STAT5A has been shown to be a tumor suppressor in ALCL cells136.  
This study reported the role of NPM-ALK in inducing DNA methylation of the 
STAT5A promoter through STAT3 activation.  This results in the epigenetic silencing 
of STAT5A expression.  Forced expression of STAT5A results in suppression of 
NPM-ALK expression and a corresponding reduction in ALCL proliferation. 
NPM-ALK mediated STAT3 signaling is also substantiated through 
coordinated expression (or lack thereof) of protein phosphatases.  ALCL tumors 
have been shown to lack expression of SHP1 tyrosine phosphatase expression 
through the methylation of its promoter137,138.  Introduction of exogenous SHP1 into 
ALCL-derived cell lines results in decreased JAK3 and STAT3 phosphorylation and 
induced the proteasomal degradation of JAK3 and STAT3120,139.  The result of which 
is the down-regulation of cyclin D3, Mcl-1 and Bcl-2 and a subsequent reduction in 
proliferation.  This represents a second example of epigenetic regulation to enhance 
STAT3 signaling and oncogenesis.  Conversely, expression of serine/threonine 
phosphatase PP2A has been shown to increase STAT3 activation through the 
removal of inhibitory serine phosphorylations111. 
STAT3 activation in ALCL is also enhanced through cytokine receptors.  
NPM-ALK induces the expression of IL-22R1 which is aberrantly expressed in these 
tumors140.  This expression leads to increased STAT3 activation and oncogenesis.  
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Similarly, IL-21R is also expressed in ALCL tumors and cell lines, although by NPM-
ALK independent mechanisms141.  STAT3 signaling and ALCL proliferation is 
substantiated by this IL-21R activation, and  IL-9 also contributes to JAK3/STAT3 
activation in ALK+ ALCL142.  Neutralizing IL-9 antibody treatment leads to cell cycle 
arrest in ALCL cells through p21 and Pim-1 dependent pathways.  Finally, IL-2Rγ 
acts as a tumor suppressor and is epigenetically silenced in NPM-ALK expressing 
cells143.  STAT3 activation via NPM-ALK results in DNA methylation at the IL-2Rγ 
promoter.  Reconstitution of IL-2Rγ results in loss of NPM-ALK expression, 







Figure 1.2:  NPM-ALK induced STAT3 signaling.  NPM-ALK activates STAT3 through direct 
phosphorylation and via JAK3 activation.  Negative regulators of NPM-ALK signaling are 
epigenetically silenced through DNA methylation by STAT3 activity (STAT5A, SHP1, IL-2Rγ).  
STAT3 activation is further propagated by cytokine signals in ALCL (IL-9R, IL21R and 
IL22R1) and through the activity of PP2A which removes inhibitory serine 
phosphorylations from STAT3.  Active STAT3 translocates to the nucleus to drive the 
transcription of genes that promote proliferation and survival.  JAK2/STAT5B activation by 




A second major signaling pathway directed by NPM-ALK kinase activity is the 
phosphatidylinositol 3’-kinase (PI3K)/AKT pathway and is typically activated by 
receptor tyrosine kinases (RTK) through the phosphorylation of PI3K (Figure 1.3)144.  
The active of PI3K then generates phosphatidylinositol-3,4,5-triphosphate (PIP3) at 
the membrane surface.  PIP3 recruits AKT (PKB) to the membrane where it is 
phosphorylated by 3-phosphoinositide dependent protein kinase-1 (PDK1) at the 
T308 residue and then becomes active.  AKT serves as a “master” kinase in this 
pathway and is responsible for an array of downstream effects.   
NPM-ALK has been shown to constitutively activate the PI3K/AKT pathway.  
Slupianek et al. reported that PI3K associates with NPM-ALK and activated AKT 
was found in both ALCL-derived cell lines and primary tumors145.  Furthermore, the 
activity of this pathway is necessary for the oncogenic phenotype driven by NPM-
ALK, as seen by inhibition of this pathway with wortmannin and LY294002 as well as 
expression of dominant negative PI3K or AKT mutants146.  The resulting activation of 
the PI3K /AKT pathway by NPM-ALK increases proliferation and survival of ALCL.  
PTEN is a phosphatase responsible for the negative regulation of this pathway by 
removing the phosphate on position 3 of PIP3 thereby stopping the signaling 
cascade147.  However, ALCL tumors have been shown to lack PTEN expression 
leading to uncontrolled PI3K/AKT signaling148. 
Active AKT phosphorylates S9-GSK3β to inhibit its enzymatic activity149.  
GSK3β is a serine/threonine kinase that marks proteins for proteasomal degradation 
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and plays a critical role in numerous signaling pathways150.  The inhibition of GSK3β 
by NPM-ALK deregulates the normal turnover of proteins affecting the cell cycle 
(CDC25A, JunB) and apoptosis (Mcl-1)149,151.  Inhibition of NPM-ALK results in the 
activation of GSK3β and the subsequent proteasomal degradation of CDC25A and 
Mcl-1.  The reduced proliferative and oncogenic capacity resulting from ALK 
inhibition can be partially rescued by GSK3β knockdown or chemical inhibition, 
which suggests that GSK3β inhibition is an important mediator of the NPM-ALK 
oncogenic phenotype. 
In addition to protecting the proteins that drive proliferation, NPM-ALK 
signaling through AKT targets proteins for degradation that inhibit proliferation.  
NPM-ALK directs the AKT dependent phosphorylation of p27Kip1, which is a cyclin-
CDK inhibitor that induces cell cycle arrest152,153,154.  NPM-ALK expressing cells 
avoid this cell cycle arrest through the constant proteasomal degradation of p27Kip1.  
Down regulation of p27kip1 is also achieved through the AKT induced 
phosphorylation of the FOXO3a transcription factor155.  The phosphorylation of 
FOXO3A results in its cytoplasmic retention and the resulting down regulation of its 
transcriptional targets p27Kip1 and Bim-1. 
The activation of the PI3K/AKT pathway also contributes to the activation of 
the Sonic Hedgehog signaling pathway in ALCL.  AKT activation results in SHH 
expression and, through the inhibition of GSK3β, the accumulation of GLI1153,156.  
SHH and GLI1 were shown to be highly expressed in ALCL-derived cell lines and 
tumors.  The expression and activation of SHH and GLI1 also positively regulate the 
activity of the PI3K/AKT pathway leading to a feed-forward loop and the dependence 
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on AKT signaling153. AKT activation also plays a role in the activation of mTOR 
resulting in the activation of S6rp, p70S6K and 4E-BP1157,158.  
 
  
Figure 1.3:  NPM-ALK induced PI3K/AKT signaling.  NPM-ALK activates PI3K to 
phosphorylate phosphatidylinositol at the membrane surface.  This recruits PDK1 to 
phosphorylate the serine/threonine kinase AKT.  PTEN is the phosphatase responsible for 
the negative regulation of this pathway and is frequently lost in ALCL.  AKT activates the 
mTOR pathway and inactivates GSK3β via serine-9 phosphorylation.  Since GSK3β targets 
Mcl-1, CDC25A, GLI-1 and JunB for degradation, these pro-proliferation and survival 
protein accumulate.  AKT also, targets p27
Kip1
 for degradation and inhibits the FOXO3a 
transcription of BIM and p27
Kip1
.  AKT signaling potentiates Sonic hedgehog signaling 




A third commonly studied signaling pathway driven by NPM-ALK is the 
mitogen-activated protein kinase (MAPK) pathway (Figure 1.4).  Activation of c-Raf, 
MEK1/2, and extracellular signal regulated kinase 1/2 (ERK1/2) was identified in 
ALCL-derived cell lines and tumor samples159.  NPM-ALK was found to activate 
MEK1/2 and ERK1/2 independent of c-Raf activity.  Importantly, the activation of this 
pathway was necessary for the transformation capabilities of NPM-ALK.  The 
activation of MEK1/2 is regulated through several signaling events.  Shp2 and Grb2 
were shown to interact with NPM-ALK and are necessary for the activation of 
MEK1/2160,161.  Additionally, NPM-ALK induces Ras activation through binding to 
Shc, PLC-γ and IRS-1 which, in turn, is necessary for ERK activation and 
downstream activity, including AP-1 transcriptional activity162.  The increased 
expression of JunB via ERK signaling is likely responsible for the increased AP-1 
expression163.  The MAPK protein Cot has also been implicated in the activation of 
ERK1/2 in the context of NPM-ALK164. 
Through activation of the Ras-ERK pathway, NPM-ALK is able to exert an 
array of downstream effects on cell proliferation and survival.  Specifically, the ERK 
activation of mTOR results in phosphorylation of S6rp and 4E-BP1157,165.  The 
mTOR activation in this context is nutrient dependent and thus involves the inhibition 
of TSC1/2 and the activation of Rheb.  The activation of mTOR results in regulation 
of expression of cell cycle mediators including cyclin A, p27 and p21 while inhibiting 
the tumor suppressor Rb165.  ERK activation also increases expression of Bcl-XL and 
CDK4 to further increase survival and cell cycle progression respectively159. 
26 
 
NPM-ALK also activates the JNK pathway166.  Active JNK and cJun is present 
in ALCL-derived cell lines and tumors and physically interacts with NPM-ALK 
through immunoprecipitation experiments.  JNK, in turn, activates cJun which 
controls the transcriptional activity of AP-1166 and expression of cyclin D3 and cyclin 
A.  Activation of cJun also down-regulates p21 allowing for increased cell cycle 
progression. 
A characteristic biomarker for ALCL is CD30 expression on the tumor cell 
surface40.  CD30 has been shown to be expressed through the NPM-ALK mediated 
ERK signaling167.  ERK activated JunB is responsible for the transcriptional up-
regulation of CD30168.  CD30 cooperates with NPM-ALK to increase survival through 








Figure 1.4:  NPM-ALK induced MAPK signaling.  NPM-ALK activates the Ras-MEK1/2-
ERK1/2 signaling pathway through several NPM-ALK interacting proteins.  IRS-1, SRC, SHC, 
and PLCγ have all been implicated in the activation of this pathway.  ERK1/2 activity 
inhibits the TSC1/2 complex which frees Rheb to activate mTOR.  This results in activation 
of p70S6K, S6RP, and 4E-BP1 and inhibition of the Rb tumor suppressor.  NPM-ALK also 
activates the MAPK protein JNK which activates the cJun transcription factor.  The 
activation of these pathways activates the transcription of pro-survival and proliferation 
genes while inhibiting the expression of cell cycle checkpoint genes. 
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Genomic and proteomic characterization of ALK 
Large scale genomics and proteomics have been immensely important tools 
for the characterization of ALK mediated oncogenesis.  Gene expression profiling 
has offered an unparalleled view of NPM-ALK driven expression patterns and 
insights into the classification of peripheral T-cell lymphomas.  Results from patient 
samples and cell lines reveal major differences between ALK+ and ALK- ALCL 
including the overexpression of BCL6, PTPN12, and CEBPB while underscoring the 
importance of the STAT3 signaling pathway170,171.  Importantly, gene expression 
profiling has provided insights into the classification of ALK+ALCL from other T-cell 
NHLs171,172. 
In addition to gene expression analysis, proteomic studies have offered 
further insight into the signaling mechanism driven by NPM-ALK.  These screening 
approaches are capable of generating novel hypotheses for the identification of ALK 
signaling mediators.  Interactome studies, either through co-immunoprecipitation or 
tandem affinity purification, were capable of identifying previously known and novel 
ALK interacting proteins173.  Specifically, Crockett et al. identified many known ALK 
interacting proteins including PI3K, JAK3, STAT3, GRB2, IRS1 and PLCγ174.  
Additionally, they identified many unknown ALK interacting proteins including those 
involved in the MAPK signaling pathway that were later validated to be important in 
ALK regulated oncogenesis (MEK1, JNK, MAPK1, etc).  Determination of the protein 
expression changes induced by NPM-ALK was carried out by Lim et al. through 
isotope-coded affinity tag (ICAT) followed by LC-MS/MS175.  This study identified the 
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NPM-ALK regulation of protein expression involved in cell proliferation, ribosome 
synthesis, survival, angiogenesis and cytoarchitectural organization. 
The use of proteomics for the identification of novel mediators of ALK 
signaling can be extended to proteins that may not physically interact with ALK 
through the use of techniques pioneered by Rush et al176. Phosphotyrosine-specific 
antibodies are used to purify the phosphoproteome prior to mass spectrometry 
analysis.  Adaptations of this technique have proven successful in the identification 
of novel mediators of ALK signaling149,160,177,178.  Interestingly, this technique was 
employed in NSCLC and resulted in the discovery of the EML4-ALK translocation in 
these tumors82.  Since NPM-ALK is a driving and constitutively active kinase in 
ALCL, these phosphoproteomic strategies are sensitive to the changes in protein 
phosphorylation under differing ALK expression and activation conditions. While 
these screening studies provide powerful opportunities for discovery, it is the 
downstream biological validation that is important for understanding ALK directed 
tumorigenesis. 
Pharmacological Inhibition of ALK 
With the identification of NPM-ALK as a driving oncogene in ALCL, ALK 
kinase inhibitors have become an area of high therapeutic interest.  Targeting ALK 
activity with small molecule inhibitors was first reported by Wan et al through the use 
of fused pyrrolocarbazoles179.  Treatment of these compounds of ALK+ ALCL 
derived cell lines resulted in decreased NPM-ALK phosphorylation and inactivation 
of downstream signaling mechanisms including STAT3, AKT and ERK1/2.  These 
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biochemical effects accompanied a decrease in cell proliferation and an increase in 
apoptosis.  These studies provided rationale for the pharmacological inhibition of 
ALK as a promising therapeutic target in cancers expressing deregulated ALK. 
The current leading compound for the inhibition of ALK is Crizotinib (PF-
02341066)180.  Crizotinib was originally designed as a c-Met (aka hepatocyte growth 
factor receptor (HGFR)) inhibitor and an improvement on the chemical structure 
known as PHA-665752.  The co-crystal structure of c-Met with PHA-665752 allowed 
for the generation of compounds with improved chemical interactions and 
pharmaceutical properties.  The lead compound, Crizotinib (2-amino-5aryl-3-
benzyloxypyridine series) has a molecular weight of 450.34 and an improved 
distribution coefficient (log D = 1.96) compared to PHA-665752180.  Crizotinib inhibits 
ALK with a cellular IC50 of 8.0 nM against c-Met.  The selectivity of Crizotinib was 
investigated against a panel of more than 120 human kinases.  Through this study, 
ALK was identified as a potent target of Crizotinib, with an IC50 of 20 nM
180.  The 
next kinase to be targeted is RON with a 10-fold less potency that c-Met.  Thirteen 
kinases are inhibited by Crizotinib within a 100-fold range of c-Met. 
Crizotinib shows strong pre-clinical efficacy in ALK and c-Met driven 
tumors181-183.  Crizotinib treatment results in cell cycle arrest, reduced proliferation 
and reduced tumor xenograft  growth in ALCL derived cell lines181.  Specifically, 
SCID-Beige mice harboring Karpas299 xenograft tumors saw a complete regression 
in tumor volume after 15 days of 100mg/kg, QD oral dose of Crizotinib.  Dosing was 
stopped at day 17 and tumors re-grew.  Interestingly, when dosing resumed on day 
62, complete regression of tumors was again observed after 14 days of treatment181. 
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Crizotinib has shown clinical success and is currently FDA approved for the 
treatment of NSCLC harboring ALK translocations184.  This clinical study on 82 
patients with ALK+ NSCLC showed a 57% response rate from Crizotinib while 33% 
of the patients retained stable disease184.  While clinical trials for Crizotinib in ALCL 
are still underway, initial findings in 2 patients with relapsed disease showed 
complete regression of lesions and report at least 5 months of sustained 
response185.  Preliminary results from clinical studies with Crizotinib in IMT showed 
one patient with complete radiographic remission following 1.5 years of Crizotinib 
treatment, while a second patient showed no response to therapy186. 
While initial treatment with Crizotinib shows broad success, the tumors have 
been shown to acquire resistance to this therapy.  Initial response to therapy lasts 
between 4 to 34 months with an average of 10.5 months187.  Mechanisms for 
Crizotinib resistance are varied.  The point mutation L1196M EML4-ALK was shown 
to be resistant to Crizotinib treatment in cell lines188. However, this mutation 
remained sensitive to other structurally distinct ALK inhibitors (NVP-TAE684 and 
AP26113).  Other mutations such as F1174L, G1202R, S1206Y and 1151Tins as 
well as EML4-ALK gene amplification were found to confer Crizotinib resistance in 
cell lines and patient samples187,189.  In addition to changes to the ALK gene, ALK+ 
NSCLC patients were shown to acquire Crizotinib resistance through the activation 
of other kinases such as KIT and EGFR.   
The clinical trials with ALK inhibitors, such as Crizotinib, have made progress 
in the treatment of ALK deregulated cancers.  However, challenges remain with the 
high chance of resistance to this form of therapy.  Further work to identify second 
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round ALK inhibitors or combined therapies will likely improve the success of 
sustained remission of these diseases. 
 
CANCER METABOLISM 
Cancer cells exhibit very different metabolic requirements than normal cells.  
While normal cells focus their metabolic needs toward energy (ATP) production, 
cancer cells on the other hand, require the synthesis of biomass (nucleotides, amino 
acids, lipids) as a fundamental necessity for cell division190.  The important 
distinction between cancer cell and normal cell metabolism was first identified by 
Otto Warburg and is generally termed the “Warburg effect” or aerobic 
glycolysis191,192.  Warburg observed that cancer cells tend to “ferment” glucose into 
lactate even under the presence of abundant oxygen and based on these 
observations, Warburg suggested that cancer arises from a defect in oxidative 
phosphorylation (Figure 1.5). 
The conceptual explanation for a cancer cell’s requirement to divert its 
metabolism away from oxidative phosphorylation lies in the limiting requirements for 
proliferating cells.  It is well known that oxidative phosphorylation is very efficient in 
producing energy, turning out 18 times more ATP than glycolysis.  However, ATP 
may not be the limiting factor in rapidly proliferating cells190,193.  Instead, a dividing 
cell must replicate its entire contents in order to successfully divide into two daughter 
cells.  It is this biomass (amino acids, lipids and nucleic acids) that becomes the 
limiting factor for cell division.  Consequently, tumor cells reduce their reliance on the 
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TCA cycle and oxidative phosphorylation.  When a molecule of glucose passes all 
the way through glycolysis and the TCA cycle, it is completely catabolized into CO2 
and H2O in an effort to extract maximal energy from every molecule of glucose.  
However, the end products of this catabolism are essentially useless to a dividing 
cell.  Instead, the shutting down of the TCA cycle allows for build-up of glycolytic 
intermediates which then can be diverted from cellular respiration and energy 
production to serve as the starting materials for biomass production190.  The 
observed increase in lactate production is a necessary byproduct of a metabolism 
based heavily on glycolysis.  NADH is consumed through glycolysis and can be 
regenerated by the conversion of pyruvate to lactate.  It is this drive to maintain the 






Much of the biomass needed for cell proliferation originates from 
intermediates of glycolysis (Figure 1.6).  Nucleotide synthesis is dependent on the 
production of ribose-5-phosphate through the pentose phosphate pathway 
originating from the upper half of glycolysis.  Lipid synthesis originates from several 
metabolites in glycolysis including glyceraldehyde-3-phosphate and 3-
phosphoglycerate as well as acetyl-CoA.  The amino acids serine glycine and 
Figure 1.5:  Metabolic programing in normal and proliferating tissues.  Normal 
differentiated tissues utilize two distinct metabolic programs based on the availability of 





through the TCA cycle and oxidative phosphorylation.  This allows for the maximal amount of 
energy to be extracted from each molecule of glucose.  In the absence of oxygen, glycolysis 
alone is used for glucose breakdown and lactate is generate to maintain redox balance.  In 
proliferating tissue including tumors aerobic glycolysis is utilized regardless of oxygen 
availability.  About 85% of glucose is converted to lactate, 5% is shuttled into the TCA cycle 
and the remaining is used to produce biomass necessary for proliferation. 
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cysteine are generated from 3-phosphoglycerate in glycolysis, while alanine can be 
generated from pyruvate.  It is this dependence on glycolytic intermediates that 




Figure 1.6:  Glycolysis provides precursors for biomass production.  Many biosynthetic 
pathways originate from glycolytic intermediates.  The pentose phosphate pathway 
which produces the ribose backbone for nucleotide synthesis originates from glucose-6-
phosphate.  Much of lipid synthesis originates from glyceraldehyde-3-phosphate.  Serine, 
glycine, and cysteine metabolism originates from 3-phospho-glycerate and also provides 
precursors for other amino acid synthesis.  Through the negative regulation of pyruvate 
kinase at the end of glycolysis, these glycolytic intermediates can accumulate and 
become available for biomass production. 
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Regulation of Cancer Metabolism by Signaling 
Cancer cells achieve this metabolic rewiring through a variety of mechanisms 
including activation of growth factor signaling, deletion of tumor suppressor activity 
and initiation of oncogenic transcriptions programs. 
PI3K/AKT/mTORC1 
The PI3K/AKT pathway is activated downstream of many growth factor 
receptors and is deregulated in many human cancers194.  The activation of AKT 
leads to increased glucose uptake and glycolytic rate195.  AKT increases expression 
of Glut1 glucose transporter and the translocation  of Glut4 to the cell surface, 
allowing for more glucose uptake into the cell196,197.   Hexokinase 1 (HK1) and 6-
phosphofructo-2-kinase (PFK-2) are also activated by AKT which traps glucose 
inside the cell and commits it to glycolysis, respectively197,198.  AKT also exerts 
metabolic control through TCA cycle driven effects.  ATP-citrate lyase (ACLY) is 
phosphorylated and activated by AKT, promoting the removal of citrate from the TCA 
cycle and directing it toward lipid synthesis199-201. 
An important downstream mediator of AKT signaling is the mTOR complex 1 
(mTORC1).  Activation of mTORC1 has been shown to regulate cell mass/size 
through the regulation of protein synthesis202.  The activation of mTORC1 by AKT is 
orchestrated through the phosphorylation and inhibition of TSC1/TSC2 complex and 
allows for the activation of mTORC1 by Rheb.  Additionally, mTORC1 is activated in 
response to cellular energy depletion, in which low ATP/AMP ratios activate AMPK 
to phosphorylate TSC2 and Raptor203,204.  mTORC1 activation regulates a broad 
37 
 
network of metabolic genes that contributes to the cancer metabolic phenotype205.  
Specifically, mTORC1 activation induces HIF-1α expression in order to drive 
expression of glycolytic genes and consequent increased glycolytic flux.  This is 
coupled with the decrease in oxidative phosphorylation through the expression of 
pyruvate dehydrogenase kinase 1 (PDK1) to inhibit PDH activity206.  Furthermore, 
mTORC1 targets SREBP expression to drive lipid synthesis and the pentose 
phosphate pathway205. 
c-Myc 
The c-Myc transcription factor also plays a major role in the reprogramming of 
cancer metabolism.  c-Myc is deregulated in many cancers and offers a mechanism 
through which metabolic reprograming occurs through gene regulation207.  Many 
glycolytic enzymes are targets of c-Myc transcriptional activity, including GLUT1, 
phosphoglucose isomerase, phosphofructokinase, glyceraldehyde-3-phosphate 
dehydrogenase, phosphoglycerate kinase, enolase and lactate 
dehydrogenase208,209.  The increased expression of glycolytic enzymes increases 
glucose uptake, glycolytic rate and lactate production, all of which are important 
contributors to the Warburg effect.  Interestingly, the increased glucose uptake by 
cancer cells has long been used for the imaging of human cancers using 18F-
fluorodeoxy-glucose positron emission tomography (18FDG-PET)210.  A recent study 
suggests that in many patients, the high level of 18FDG uptake is likely due to 
deregulation of c-Myc in the tumor cells211. 
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Apart from its role in up-regulating glycolysis, c-Myc exerts control over 
mitochondrial biogenesis and respiration.  Overexpression of c-Myc causes an 
increase in mitochondrial mass and oxygen consumption212.  While this may seem 
counterproductive to the aim of the Warburg effect, the increased mitochondrial 
activity is a result of c-Myc driven glutamine metabolism.  c-Myc increases glutamine 
uptake through the induction of glutamine transporters ASCT2 and SLC7A5213.  
Also, glutamine catabolism is increased through the expression of mitochondrial 
glutaminase (GLS).  c-Myc represses expression of miR-23a/b which down 
regulates GLS levels.  This increased glutaminolysis provides carbon and nitrogen 
molecules to biomass production, as well as feeding into the TCA cycle as α-
ketoglutarate for increased energy production.  The role of c-Myc driven glutamine 
metabolism offers a counterview of the Warburg effect, in which glycolysis is 
uncoupled from the TCA cycle and cancer cells become addicted to both glucose 
and glutamine. 
Regulation of glycolysis 
 Cancer cells adapt ways to tightly regulate glycolysis in order to drive 
biomass production.  Pyruvate kinase M2 (PKM2) can be phosphorylated by growth 
factor receptors to reduce its activity214.  This will be discussed further in the next 
section.  However, the reduced PKM2 activity corresponds to an alternate glycolytic 
pathway that takes place in many cancer cells.  Pyruvate is generated in the 
absence of PKM2 activity through the donation of the phosphate on 
phosphoenolpyruvate (PEP) to phosphoglycerate mutase (PGAM1)215.  This 
phosphorylated PGAM has increased activity and thus leads to a positive feedback 
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loop which increases pyruvate and lactate generation.  Furthermore, PGAM1 activity 
provides feedback to the biomass producing pathways.  3-phosphoglycerate (3-PG) 
(substrate of PGAM1) inhibits the pentose phosphate pathway through binding to 6-
phosphogluconate dehydrogenase (6PGD), while 2-phosphoglycerate (product of 
PGAM1) activates 3-phosphoglycerate dehydrogenase (PHGDH) which drives 
serine biosynthesis216. 
Lactate production through the activity of lactate dehydrogenase (LDH) is also 
highly regulated in cancer metabolism.  While increased LDH expression levels are 
driven by HIF-1α and c-Myc, posttranslational regulation of LDH is also important in 
regulating cancer growth209,217.  Fibroblast growth factor receptor (FGFR1) 
phosphorylates LDHA at the Y10 and Y83 residues and results its increased 
enzymatic activity and increased lactate production.  Lactate production is necessary 
to maintain the NADH/NAD+ redox balance218.  The blocking of LDHA 
phosphorylation results in a shift toward oxidative phosphorylation in order to obtain 
a similar redox balance.  The increased lactate production in cancer cells, not only 
helps to balance the redox potential in cells operating under aerobic glycolysis, but it 
fuels respiration as well.  Tumors contain hypoxic as well as oxygenated regions as 
a result of the poor blood supply feeding them.  Therefore, the cells in the tumor that 





Pyruvate Kinase M2 
One of the genes that have been implicated in driving the Warburg Effect is 
Pyruvate Kinase M2 (PKM2).  Pyruvate kinase is the enzyme responsible for 
catalyzing the final step in glycolysis: the conversion of phosphoenolpyruvate to 
pyruvate while producing ATP.   It exists in four isoforms which differ in their tissue 
distribution and activity (Table 1.2).  Pyruvate kinase L (PKL) isoform is expressed in 
liver, kidney and intestinal tissues while Pyruvate kinase R (PKR) isoform is 
expressed in erythrocytes220.  PKM1 isoform is expressed in brain and muscle tissue 
and has no known regulators of its high level of activity.  Finally, PKM2 is the isoform 
that is expressed in all proliferating cells including embryonic cells, adult stem cells 
and tumor cells, giving it the classification as the “tumor specific” isoform.  While 
PKL and PKR are encoded by separate genes, PKM1 and PKM2 are splice variants 
of the same gene (PKM) (Figure 1.7).  Skipping exon 9 and including exon 10 results 
in the production of a regulatable form of pyruvate kinase (PKM2).  It was recently 
shown that PKM2 helps to drive tumor growth and that this is reversed with forced 






Table 1.2:  Isoforms of pyruvate kinase 
Figure 1.7:  Sequence alignment of PKM1 and PKM2. Sequence alignment of PKM1 and 
PKM2 shows region of differential exon splicing between residues 389 and 433.  Circles 




PKM2 in its most active state exists as a homo-tetramer.  The binding of its 
allosteric regulator fructose-1,6-bisphosphate (FBP) locks PKM2 into its tetramer 
form increasing its activity222.  When this tetramer is disrupted, the resulting dimer 
form of PKM2 is significantly less active.  It is this ability for PKM2 to be regulated 
(unlike PKM1) that is utilized by tumor cells to adjust their metabolism to favor 
growth and proliferation.  By reducing the activity of PKM2, the metabolites flowing 
through glycolysis become backed-up and start to accumulate in the cell.  This 
allows for the diversion of these metabolites into alternative metabolic pathways 
designed for the production of biomass (Figure 1.8). 
 
 
Figure 1.8:  Regulation of PKM2 activity.  In its most active state, PKM2 exists in a 
tetramer conformation, stabilized by FBP.  The rapid conversion of PEP to pyruvate 
supports oxidative metabolism in which pyruvate is catabolized in the TCA cycle.  The 
tetramer can be disrupted via phosphorylation of PKM2 or through binding to 
phosphorylated peptides.  The resulting dimer conformation is less active and allows for 
the accumulation of glycolytic intermediates, which can be used for biomass production. 
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Cancer cells have been shown to regulate PKM2 in several ways.  The first 
was observed when PKM2 was found to be a phosphotyrosine binding protein223.  
Here, PKM2 was found to bind to peptides containing phosphotyrosine residues.  
The consequence of this was the disruption of FBP binding and inhibition of PKM2 
enzymatic activity.  This leads to the diversion of metabolites to anabolic processes 
that support cell growth.  Since many tumors have abundantly active tyrosine kinase 
signaling, the phosphotyrosine binding properties of PKM2 provide the nexus 
between oncogenic kinase signaling and tumor metabolism. 
A second observation on how PKM2 is regulated by cancer cells came in the 
more direct link between kinase signaling and PKM2 activity.  A phosphoproteomic 
screening of ZNF198-FGFR1 expressing cells identified several PKM2 tyrosine 
residues as potential phosphosites regulated by this constitutively active oncogene 
(Figure 1.7)224.  It was discovered that Y105 of PKM2 can be directly phosphorylated 
by FGFR1 as well as several other oncogenic tyrosine kinases.  This Y105 
phosphorylation was also shown to disrupt FBP binding and thus inhibit PKM2 
enzymatic activity, resulting in a proliferative advantage.   
PKM2 has become a promising target for the therapeutic intervention of 
cancer metabolism.  PKM2 activating compounds have shown feasible in pre-clinical 
studies to regulate tumor growth225,226.  Although these reagents are not particularly 
cytotoxic, they do reduce proliferation and limit tumorigenesis, providing rationale for 
PKM2 activation in a clinical setting225.  Interestingly, several groups are also 
developing PKM2 inhibitors and cancer therapeutics227-229.  The rationale follows that 
PKM2 is selectively expressed in tumor cells and is necessary for oncogenesis.  
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Shikonin is one active compound that has inhibitory effects on PKM2.  Interestingly, 
Shikonin selectively inhibits PKM2 while PKM1 is unaffected, allowing for efficient 
tumor targeting228.  PKM2 inhibitors can decrease the rapid glycolytic rate that is 
characteristic of tumor cells and induce cell death229.  The fact that PKM2 activators 
and inhibitors are promising anti-cancer agents, makes the oncogenic regulation of 
this enzyme highly important.  This suggests that either completely active or 
completely inactive PKM2 is detrimental to oncogenesis and finding the “sweet spot” 
in enzymatic activity is necessary for metabolic reprogramming and biomass 
generation.  Alternatively, new roles for PKM2 in transcriptional regulation and 
protein phosphorylation have recently been uncovered230-234.  To date, the PKM2 
activators and inhibitors have only been tested against the ability of PKM2 to convert 
PEP to pyruvate and it is unclear how they affect PKM2’s other cellular roles. 
SUMMARY AND RATIONALE 
Mutations involving the ALK gene are involved in the pathogenesis of many 
cancer types.  A comprehensive understanding of the signaling mechanisms driven 
by ALK to induce oncogenesis is necessary for the development of effective 
therapeutic agents that target these cancers.  Furthermore, while other tyrosine 
kinases have been shown to induce metabolic changes, the role for ALK in 
metabolic regulation is unknown.  The following studies aim to identify novel 









Integrated Phosphoproteomic and Metabolomic Analysis Reveals NPM-ALK 
Driven Metabolic Reprogramming 
ABSTRACT 
The mechanisms underlying the pathogenesis of NPM-ALK expressing 
anaplastic large cell lymphoma (ALCL) are not completely understood.  To identify 
novel mediators of NPM-ALK signaling we pursued an unbiased phosphoproteomic 
screen.  Many metabolic proteins and pathways were shown to be altered by NPM-
ALK activity.  Therefore, an untargeted metabolomics screen was utilized to 
characterize the metabolic changes driven by NPM-ALK activity. Dramatic metabolic 
changes were observed in glycolysis and many of the biomass producing pathways.  
Integrating the phosphoproteomic and metabolomic data highlighted the changes in 
glycolysis, TCA cycle and nucleotide metabolism.   Metabolic flux analysis 
characterized the carbon flux through these key pathways and illustrated a NPM-
ALK driven metabolic shift from energy production toward biomass production.  
These data establish the first link between NPM-ALK and metabolic regulation while 





Anaplastic large cell lymphoma (ALCL) is a subtype of peripheral T-cell 
lymphoma representing 3% of adult non-Hodgkin lymphomas and 10-15% of all 
childhood lymphomas40.  They are aggressive tumors characterized by large cells 
with abundant cytoplasm and multiple pleomorphic nuclei.  The World Health 
Organization (WHO) classification of lymphoid malignancies recognizes two forms of 
systemic ALCL based on the presence of chromosomal translocations in the 
anaplastic lymphoma kinase (ALK) gene47.  The t(2;5)(p23;q35) translocation 
involves ALK gene at 2p23 locus and the Nucleophosmin (NPM) gene at 5q35 and 
is present in more than 80% of pediatric ALCLs. The resulting expression of the 
constitutively active tyrosine kinase (NPM-ALK) drives oncogenesis in these 
tumors49.  ALK encodes a receptor tyrosine kinase of the insulin receptor 
superfamily which is involved in neural development35.  Mutations of the full length 
ALK receptor have been identified in a subset of sporadic and inherited 
neuroblastomas101.  The oncogenic potential of NPM-ALK has been demonstrated 
by its ability to activate numerous canonical growth factor signaling pathways 
including PI3K/AKT, JAK/STAT, PLCγ112,145,149,174,175,235.   
Cellular reprogramming of energy metabolism is an emerging hallmark of 
cancer 236.  Metabolic reprogramming via the “Warburg effect”  is characterized by 
alternate glycolysis and increased lactate production even in the presence of 
abundant oxygen 192.  While resting cells need to continuously produce energy, 
proliferating neoplastic cells shift their metabolism toward biomass (nucleic acids, 




Recent technical developments in large-scale mass spectrometry-based 
phosphoproteomic analysis have demonstrated the powerful potential for rapid 
discovery of multiple kinase substrates that are deregulated in cancer 237,238.  The 
analysis of phosphoproteins at a global level has been a technical challenge due to 
a number of factors including their low abundance, lability of the phosphorylation and 
substoichiometric phosphorylation-site occupancy of phosphoproteins239. Thus, 
robust methods to isolate maximal number of phosphopeptides with high 
reproducibility and specificity are required to carry out phosphoproteome analysis.  
Metal oxide affinity chromatography (MOAC) followed by immunoprecipitation using 
phosphotyrosine-specific antibodies (pY-IP) to enrich for phosphotyrosine (pY) 
peptides followed by standard LC-MS/MS analysis for large scale identification of 
phosphopeptides and phosphorylation sites have been successfully used to identify 
signaling proteins in cancer178.  Similarly, metabolomic profiling using GC/LC-MS 
represents a powerful method for unbiased global measurement of small molecules 
that impact various aspects of cancer metabolism240.  Integration of these two 
powerful large scale approaches has not been explored to elucidate the 
pathogenesis of NPM-ALK positive ALCL.   
To identify novel proteins/pathways that mediate NPM-ALK signaling, we 
employed a phosphoproteomic study which revealed that numerous proteins within 
cellular metabolic pathways were regulated by NPM-ALK.  Thus, we explored the 
hypothesis that NPM-ALK regulates cellular metabolism to promote tumorigenesis.  
We subsequently carried out a mass spectrometry-based metabolomic study in 
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order to characterize the NPM-ALK-driven metabolic signature.  Integrated analysis 
of the phosphoproteomic and metabolomic studies led to the discovery and 
characterization of a metabolic switch induced by NPM-ALK.  These studies provide 
a link between NPM-ALK signaling and metabolic regulation on a global scale.  We 
also point to specific modes of metabolic regulation that drive biomass production 
which is necessary for tumor cell proliferation. 
MATERIALS AND METHODS 
Cell Culture:  All ALCL-derived cell lines (SU-DHL-1, DEL, Karpas299, SUPM2) 
were maintained in RPMI 1640 supplemented with 10% FBS in 5% CO2 humidified 
incubators.   
Compounds: ALK inhibitor CEP-26939 (CEP) was acquired from Cephalon 241. 
PKM2 activators NCGC00186528 (TEPP-46) and NCGC00186527 (NCGC-527) 
were provided by the NIH Chemical Genomics Center.  Both compounds are from 
the thieno-[3,2-b]pyrrole[3,2-d]pyridazinone chemical class 225. 
Phosphoproteomics:  Sixty million cells were treated for 6 hours with CEP or DMSO.  
Cells were lysed with 9M urea/20mM HEPES pH8.0/0.1%SDS and a cocktail of 
phosphatase inhibitors (sodium orthovanadate, sodium pyrophosphate and β-
glycerophosphate).  For each sample, 6mg of protein were reduced with 4.5mM DTT 
for 30min at 60°C, alkylated with 10mM iodoacetamide for 30min at room 
temperature in the dark and then digested with trypsin overnight at 37°C.  Samples 
were desalted on a C18 cartridge (Sep-Pak plus C18 cartridge, Waters), then dried 
before any further processing. Each sample was prepared in triplicate.  Metal oxide 
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affinity chromatography (MOAC) was performed using titanium dioxide (TiO2) 
microparticles from GL Sciences Inc (Titansphere® Phos-TiO, GL Sciences Inc., 
Torrance, CA) in a microparticles-to-protein ratio of 6/1 (w/w).  Hydrophilic 
phosphopeptides were eluted with 5% ammonium hydroxide solution and 
hydrophobic phosphopeptides were eluted with 5% pyrrolidine solution. After elution, 
peptides were dried. The equivalent of 5mg of protein was further enriched for 
phosphorylated tyrosine peptides by overnight immunoprecipitation using a cocktail 
of anti-phosphotyrosine antibodies (4G10, Millipore /PT-66, Sigma/p-Tyr-100, Cell 
Signaling Technology). After elution, phosphotyrosine peptides were dried.  
Samples from MOAC were reconstituted in 25μl loading buffer (0.1% TFA/2% 
acetonitrile) while samples from MOAC followed by pY-IP were reconstituted in 35 μl 
loading buffer.  LTQ Orbitrap XL(ThermoFisher) in-line with Paradigm MS2 (Michrom 
bioresources) was employed for acquiring high-resolution MS and MS/MS data. Ten 
μl of the peptides was loaded onto a sample trap (Captrap, Bruker-Michrom) that 
was in-line with a nano-capillary column (Picofrit, 75μm i.d.x 15μm tip, New 
Objective) packed in-house with 10 cm of MAGIC AQ C18 reverse phase material 
(Michrom Bioresource). Two different gradient programs, one each for MOAC and 
phosphotyrosine immunoprecipitation samples, were used for peptide elution. For 
MOAC samples, a gradient of 5-40% buffer B (95% acetonitrile/1% acetic acid) in 
135 min and 5 min wash with 100% buffer B followed by 30 min of re-equilibration 
with buffer A (2% acetonitrile/1% acetic acid) was used. For phosphotyrosine 
immunoprecipitation samples, which were much less complex mixture of peptides, 5-
40% gradient with buffer B was achieved in 75 min followed by 5 min wash with 
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buffer B and 30 min re-equilibration. Flow rate was ~0.3μl/min. Peptides were 
directly introduced into the mass spectrometer using a nano-spray source. Orbitrap 
was set to collect 1 MS scan between 400-2000 m/z (resolution of 30,000 @ 400 
m/z) in orbitrap followed by data dependent CID spectra on top 9 ions in LTQ 
(normalized collision energy ~35%). Technical duplicate data for each of the MOAC 
and triplicate data for phosphotyrosine immunoprecipitation samples were acquired.  
RAW files were converted to mzXML using msconvert. The mass spectrometry data 
was then searched with the Swissprot Human taxonomic protein database (2012_04 
release) appended with common proteomics contaminants and reverse sequences 
as decoys. Searches were performed with X!Tandem (version 2010.10.01.1 ) using 
the k-score plugin.  The search results were then post-processed through the Trans-
Proteomic Pipeline (TPP) using PeptideProphet and ProteinProphet.  Spectral 
counts for the Trans-Proteomic Pipeline (TPP) results were obtained for each cell 
line using the spectral counting software ABACUS. 
Metabolomics:  Samples were removed from -80°C storage and placed on ice for the 
duration of the experiment.  Triple-distilled H2O (300 µL) was added to each sample 
tube containing a frozen pellet, and two Process Blanks (PB) were created by 
placing same volume of H20 into empty tubes. Samples were re-suspended, 
transferred to the wells of a 1mL deep-well plate containing 2-3 3mm glass beads 
and homogenized for 5 minutes at room temperature (RT) by a Hard Tissue 
homogenizer (VWR).  
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Protein concentration was determined by mixing of a 2µL aliquot of homogenized 
sample with 198µL of Bradford reagent (Sigma B6916). Assay was performed at RT 
in a clear, flat bottom, shallow 96-well plate.  The plate was vortexed and absorption 
data collected on BioTek uQuant with KC Junior software (v1.41.8) within 15 
minutes after mixing sample and reagent.  A 14 point calibration curve was created 
using bovine albumin (Sigma B4287). All measurements were performed in 
duplicate on the same plate. 
Sample volumes for metabolomic analyses were determined by normalization to a 
protein content of 8 mg/mL using the formula: 8/x (mg/mL) *100= µL sample volume 
aliquoted.  Pooled human plasma controls (HB, pooled human plasma from in-house 
reserve of American Red Cross supply stored at -80°C) were processed in parallel 
with other samples following this step. 
For de-proteination the calculated volume of each sample was transferred to a 2mL 
deep-well plate and diluted  with 8 volumes of 100% ethanol containing 13C algal 
amino acid mixture (Sigma-Aldrich 426199) as a recovery standard. The plate was 
then vortexed, centrifuged at 4750 RPM, 4°C for 10 min, and supernatant 
transferred to a new 2 mL deep-well plate.  A pre-washed filter plate (Nunc 278010) 
was attached and the assembly centrifuged at 4750 RPM, 4°C for 10 min to further 
clarify the samples.  
Two identical aliquots of each sample were transferred into glass inserts placed in 
custom-made 96 well aluminum plates and dried down under the stream  of nitrogen 
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for 1.5 hr. One set of the aliquots was than prepared for GC-MS analysis and 
another for LC-MS.  
LC-MS Method: Dried LC-MS samples were re-suspended in H2O(27µL) containing 
injection standards (tBoc-L-Alanine, tBoc-L-Asparagine, tBoc-L-Phenylalanine). Two 
solvent blanks (SB, 100% H2O with t-Boc standards) and 2 water blanks (BB, 100% 
H2O) were added at the end of the sample prep.   All samples were then capped, 
vortexed at 2000 RPM for 2 minutes, and transferred to the instrument for analysis.  
Samples were analyzed on an Agilent 1200 LC / 6530 qTOF LC-MS system using a 
Waters Acquity HSS T3 reversed-phase column (1.8 µ, 50 mm x 2.1 mm ID).  For 
positive ion detection, mobile phase A was 100% water with 0.1% formic acid and 
mobile phase B was 100% methanol with 0.1% formic acid.  For negative ion 
detection, formic acid was replaced with 0.1% ammonium bicarbonate.  The gradient 
was as follows: 0-0.5 min 1% B, 0.5-2 min 1-99% B, 2-6 min 99% B, 6-9 min 1% B.  
The flow rate was 0.35 mL/min and column temperature kept at 40°C.  The injection 
volumes for positive and negative mode were 7 µL and 12 µL respectively.  
Jetstream ESI source gas temperature was set to 350°C, drying gas flow rate - 10 
L/min, nebulizer pressure - 30psig, sheath gas temperature - 350°C and flow rate - 
11 L/min.  Capillary current was set to 10.0 µA and VCap voltage - to 3500V. Inline 
mass calibration was performed by delivering reference masses through a dedicated 
inlet on mass spectrometer. Reference masses were 99.09 and 922.009 m/z 
(Positive mode) and 62.0009 and 981.9956 M/Z (Negative mode). Data analysis was 
performed using Find by Formula algorithm of the Agilent MassHunter Qualitative 
analysis software. Library for the analysis was constructed partially from the 
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authentic standards and partially by creating “Known Unknowns” from mass spectral 
features consistently present in a large proportion of the samples. Molecular features 
were identified by Molecular Feature Extractor (Agilent MassHunter component) and 
processed using in-house software. 
GC-MS Method: The duplicate plate destined for GC analysis was transferred to a 
dry box (nitrogen atmosphere) and 60µL of derivitization reagent (BSTFA in 
anhydrous pyridine containing butylated hydroxytoluene as a derivatization 
standard) was added to each dried sample.  Process blanks, solvent blanks (SB, 
100% derivative reagent) and blank blanks were processed identically. Samples 
were sealed using crimp-caps, and the plate was removed from the dry box, 
vortexed (2000 rpm, 2 min), and incubated (60°C, 30 min) on a heat block. The GC 
plate was allowed to cool to RT, then transferred to the GC autosampler. GC 
analyses were done on an Agilent 7890A-5975C inert XL MSD GCMS instrument.  
Samples were injected (1 uL, split 10:1, 250C) onto a HP-5MS 5% phenyl-methyl 
Silox (30 m x 250 uM x 0.25 uM) column and eluted (1 mL/min H2, 60C(0.5 min 
hold), 10 C/min to 80C, 50 C/min to 325C,  4.5 min at 325C for 11.9 min total run 
time), transferred to the MSD unit (280C), ionized (EI, 70V), and scanned from 800-
50 m/z after a solvent delay of 3 min (source 230C, quad at 150C).  Data was 
analyzed using Agilent CHEMSTATION software. 
Metabolomic Pathway Analysis:  MetaboAnalyst 2.0 was used to generate significant 
pathways in metabolomics dataset.  The raw data was inserted into the software and 
the phenotype label was set to “discrete” (DMSO vs. CEP).  Identified compounds 
were matched based on KEGG ID.  Missing values were replaced by a small value.  
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The data was normalized by creating a pooled average sample from DMSO group.  
No data transformation or data filtering was applied, while data was scaled by 
autoscaling (mean-centered and divided by the standard deviation of each variable).  
Global test was used for pathway enrichment analysis and out-degree centrality was 
used for pathway topology analysis.  The p-value is assigned based on the coverage 
and change observed in a given metabolic pathway.  A pathway impact score was 
assigned based on the location of the identified metabolites in a given pathway.  A 
significant threshold was assigned at y=1/x for subsequent analysis.  As a control, 
the same analysis was conducted with DMSO vs. DMSO to establish that the P 
value was not biased toward the coverage of metabolic pathways as the data is 
restricted to those metabolites that have been validated.   
Metabolic Flux:   Cells were treated with DMSO or CEP (300nM) for 6 hours in 
serum free media.  Media was then changed to one containing 13C-glucose for or 30 
minutes.  A mixture of methanol chloroform and water were used to extract 
metabolites from pelleted cells.  Following centrifugation at 10000rpm for 5 min, 
supernatant containing metabolites were transferred to autosampler vials for LC-MS 
analysis.  Agilent 1200 chromatography (Santa Clara, CA), Luna (Phenomenex, 
Torrance, CA) NH2 HILIC (hydrophilic interaction chromatography) column was 
used for chromatographic separation.  Agilent 6200 series Time-of-flight mass 
spectrometer was used for detection and quantification.  Data were processed by 






Phosphoproteomic analysis reveals NPM-ALK-mediated phosphorylation of 
metabolic proteins   
We utilized a mass spectrometry-based phosphoproteomic strategy aimed at 
the identification of novel mediators of NPM-ALK signaling (Figure 2.1).  A two-
phase enrichment strategy that allows for the identification of serine, threonine and 
tyrosine phosphorylated peptides was used for LC-MS/MS.  All experiments were 
conducted in biological triplicates with an NPM-ALK+ ALCL cell line (SU-DHL-1). 
 
 
Prior to analyzing the phosphoproteome under ALK inhibition conditions, 
several cell lines were subjected to this analysis without drug treatment (Figure 2.2).  
The ALK+ cell lines SU-DHL-1 and DEL (Figures 2.2A and B, respectively) portray a 
Figure 2.1: Integrated phosphoproteomic and metabolomic experimental design.  NPM-
ALK+ cell lines were exposed to ALK inhibitor (CEP) or DMSO.  Phosphorylated peptides were 
enriched with metal oxide affinity chromatography (MOAC) followed by 
immunoprecipitation with pY antibodies and subjected to tandem mass spectrometry 
analysis.  For the metabolomics, the cell lysates were subjected to liquid chromatography 
mass spectrometry (LC-MS) in both positive and negative mode, as well as gas 
chromatography mass spectrometry (GC-MS).  
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characteristic phosphoproteomic signature for cells expressing a constitutively active 
kinase.  Plotting the number of proteins on the y-axis vs. number of 
phosphopeptides identified for each protein on the x-axis, reveals ALK as an 
extreme outlier (23 and 24 unique ALK phosphopeptides identified for SU-DHL-1 
and DEL cell respectively).  This was expected since ALK is known to be 
constitutively active and highly expressed in these cell lines.  The interquartile range 
(IQR) was used as a threshold from which we identified known and novel ALK 
signaling mediators.  Some of these were identified in Figure 2.2 (STAT3, SHC1, 
IRS-1 from SU-DHL-1 and PIK3AP1, SHC1 from DEL).  Conversely, OCI-LY10 (a 
DLBCL cell line with no known driving oncogenic kinase) cells showed a very 
different phosphoproteomic signature (Figure 2.2C).  Only 64 phosphorylated 
proteins were identified compared to over 200 for the ALK expressing cells.  
Furthermore, no outlier was identified and the IQR analysis finds very few proteins to 






Figure 2.2:  Phosphoproteome signature for lymphoma cell lines.  The number of 
phosphopeptides for each protein is plotted against the number of phosphoproteins for 
ALK+ALCL cell lines SU-DHL-1 (A) and DEL (B) and DLBCL cell line  OCI-Ly10 (C).  Interquartile 
range (IQR)is plotted along with ALK and known ALK substrates. 
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Given the known phosphoproteomic signatures of NPM-ALK expressing cells, 
we repeated these analyses in the presence of an ALK inhibitor identify proteins that 
changed in this signature.  CEP-26939 (CEP) was used to inhibit ALK kinase 
activity.  This compound has a cellular IC50 of 100nM and remarkable selectivity at 
this concentration (Figure 2.3A)241.  To determine the optimal conditions for these 
proteomic studies, various drug concentrations and time courses of ALK inhibition 
were evaluated.  Inhibition of ALK tyrosine kinase activity using CEP (300nM for 6 
hours) was associated with complete abrogation of autophosphorylation at Y1604-
ALK in NPM-ALK+ALCL cell lines (SU-DHL-1 and SUPM2) without impacting cell 
viability (Figure 2.3B-C).  These conditions were used in subsequent 
phosphoproteomic experiments.   MS-based phosphoproteomic analysis of ALCL-
derived cell lines revealed that inhibition of ALK resulted in the down-regulation of 
569 proteins and up-regulation of 102 proteins.  Z-score analysis was used to group 
proteins based on the directionality and significance of change after ALK inhibition 
(representative data from 1 biological replicate (technical triplicate) of SU-DHL-1) 
(Figure 2.4).  As expected, the phosphoprotein that changed with greatest 
significance in response to ALK inhibition was ALK (z-score=-6.0 with 93 spectral 
counts identified in DMSO treated cells and 1 spectral count in CEP).  This result 
provided confidence in the efficacy of ALK inhibition in this experiment.  We 
established a significance threshold of │z│≥1 (proteins that changed with greater 
than or equal to 1 standard deviation from the DMSO control) for the identification of 
candidate mediators of ALK signaling.  Forty-nine proteins met this statistical 
criterion, including previously known ALK substrates including STAT3 (z=-2.2) and 
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SHC-1 (z = -3.6)49,113.   Pyruvate kinase M2 (PKM2) was identified with a z-score  




Figure 2.3:  Validation of conditions for phosphoproteomic studies.  (A)  Structure of ALK 
inhibitor CEP-26939.  (B) Immunoblots of SU-DHL-1 and SUPM2 cell lysates treated with 
300nM CEP for 6hrs in 1% FBS.  (C) The same treatment conditions from (C) were used to 





In order to functionally categorize the observed changes in the 
phosphoproteins, we utilized the Database for Annotation, Visualization and 
Integrated Discovery (DAVID)242,243 (Figure 2.5A-B).  Gene Ontology (GO) biological 
process term analysis identified numerous processes that are regulated by NPM-
ALK activity.  The list of significantly represented GO terms include “RNA 
processing”, “gene expression”, “transmembrane receptor tyrosine kinase (RTK) 
signaling pathway”, “positive regulation of cell proliferation”, and “cell cycle process” 
among others (Figure 2.5A).  Interestingly, the GO term “metabolic process” was 
also significantly (p=0.0003) represented in our data set.  Further analysis of the  
“metabolic process” GO term into its constituents revealed the alterations of 
metabolic pathways (Figure 2.5D) such as “nucleotide metabolic process”, “nitrogen 
Figure 2.4:  Phosphoproteome changes in response to ALK inhibition.  Changes in 
spectral counts following NPM-ALK inhibition are quantified by z-score.  The number of 
proteins (frequency) with a given z-score value are plotted against the z-score.  A 




compound metabolic process”, “RNA metabolic process”, “macromolecule metabolic 
process”, “biosynthetic process” and “glycolysis”.   
 
 
Table 2.1 lists phosphoproteins clustered based on the KEGG annotated 
metabolic pathways that were identified by the phosphoproteomic analysis to be 
regulated by ALK activity.  The raw spectral counts identified for each 
phosphoprotein under both DMSO and CEP treated conditions are tabulated.  Data 
from both metal-oxide affinity chromatography (MOAC) for the serine/threonine 
phosphoproteome and the MOAC followed by phosphotyrosine immunoprecipition 
(pY-IP) for the tyrosine phosphoproteome are shown.  As demonstrated in Table 2.1, 
many proteins were identified in both the serine/threonine and tyrosine datasets.   
The “Merged Difference” column displays the combined data from all three biological 
replicates as represented by the change in spectral counts following ALK inhibition.  
Figure 2.5:   Biological process enrichment in phosphoproteomic data.  (A)  Gene Ontology 
(GO) term enrichment analysis using DAVID applied to the proteins that changed in spectral 
counts following ALK inhibition.  A subset of the significant terms is displayed.  (B)  List of GO 
terms that comprise the “metabolic processes” term. 
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Several key phosphoproteins in glycolysis were identified to be differentially 
phosphorylated following NPM-ALK inhibition.  Specifically, the abundance of 
phosphorylated peptides derived from PKM2 and Lactate dehydrogenase B (LDHB) 
were decreased; 28 for PKM2 and 14 for LDHB.  Serine phosphorylation of 
phosphoglucomutase 1 (PGM1) (a regulator of the pentose phosphate pathway) was 
increased by 16 spectral counts after ALK inhibition.  Additionally, large changes 
were seen in phosphoproteins in nucleotide metabolism including thioredoxin 
reductase 1 (TXNRD1) (increase of 10 spectral counts), nudix-type motif 5(NUDT5) 
(decrease of 9 spectral counts) and 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase (ATIC) (increase of 7 spectral counts).  Based 
on these results, we hypothesized that NPM-ALK regulates cellular metabolism via 
phosphorylation of proteins involved in key metabolic pathways including glycolysis, 





Table 2.1: Phosphoproteomic results for metabolic proteins.  
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Metabolomic analysis reveals NPM-ALK-mediated alterations in biomass 
producing pathways  
Based on robust enrichment of metabolic proteins that were regulated by 
NPM-ALK (Table 2.1), we carried out metabolomic profiling of ALCL-derived cells in 
the presence or absence of ALK activity. Metabolites were extracted from lysates of 
4 NPM-ALK+ ALCL-derived cells (SU-DHL-1, DEL, SUPM2, SR786) subjected to 
identical conditions used for the phosphoproteomic studies and analyzed using three 
independent metabolomics platforms: ultrahigh performance liquid chromatography-
tandem mass spectrometry (UHLC-MS/MS) in negative and positive ion modes as 
well as gas chromatography (GC)-MS.   Metabolite levels in cells with and without 
ALK inhibition were analyzed in biological quadruplicate (See Figure 1A for overall 
experimental design for metabolomics profiling).  As shown in Figure 2.6, we 
observed large scale and global changes in metabolites (mass spectral features) in 
response to ALK inhibition.  About a quarter (23.6%) of the 4784 mass spectral 
features from SU-DHL-1 cells changed with an average z-score of greater than 2 or 
less than -2 (Figure 2.6A).  Z-score analyses for the other cell lines tested are shown 
in Figures 2.6B-D.  Of the 4673 mass spectral features identified in SUPM2 cells, 
11% of these changed with │z│>2.0 (Figure 2.6B).  DEL and SR786 cells revealed 
17% and 6% of the 4701 and 4638 mass spectral features, respectively to change 






The apparent variability in metabolic response to ALK inhibition across cell 
lines led us to characterize these differences.  Random forest analysis244 was used 
to cluster the DMSO treated cell lines based on their metabolomic profiles (Figure 
2.7A).  Importantly, the replicates for each cell lines clustered tightly together 
suggesting that the observations were reproducible amongst replicates.  However, 
Figure 2.6: Metabolomic analysis reveals widespread metabolic changes driven by NPM-
ALK signaling.  Z-score analysis of all identified mass spectral features that change in 
response to NPM-ALK inhibition.  Each feature is represented in biological quadruplicate.  
Blue dots: DMSO.  Red dots: CEP treated (A) SU-DHL-1 (B) SUPM2  (C) DEL  (D) SR786 
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each cell line clustered independently.  This suggests that each cell line exhibits a 
distinct metabolic phenotype even in the presence of NPM-ALK.  These differences 
may be accounted for by the unknown secondary mutations that exist in these cell 
lines that could be impacting metabolism.  Random forest analysis was also used to 
determine the metabolic impact of ALK inhibition.  SU-DHL-1 (Figure 2.7B), SUPM2 
(Figure 2.7C) and DEL (Figure 2.7D) cells showed clustering differences between 
DMSO and CEP treated cells, as evident by the ability to separate the groups by a 
straight line.  This suggests that ALK inhibition significantly alters the cellular 
metabolism to the extent that the two conditions represent different metabolic 
entities.  However, SR786 cells (Figure 2.7E) did not show efficient clustering 
amongst treatment groups, suggesting ALK inhibition has less metabolic 





Figure 2.7:  Random Forest analysis reveals metabolic differences in ALCL cells and ALK 
regulated metabolism. (A) Random Forest analysis on metabolomics data from 4 ALCL cell 
lines.  Random Forest analysis on metabolomics data from SU-DHL-1 (B), SUPM2 (C), DEL (D) 





To determine what overlap exists between cell lines, the z-score analysis for 
each cell line was combined and metabolites that significantly changed (│z│>1.0) in 
at least 2 of the 4 cell lines were tabulated (Table 2.2).  Metabolites that increased in 
response to ALK inhibition were highlighted red while those that decreased were 
highlighted green.  Metabolites that lacked significant change remained uncolored.  
Several metabolites were consistently upregulated, such as o-phospho-DL-serine, 
nicotinamide, and 3’-CMP.  These metabolites might serve as biomarkers for ALCL, 
but further investigation is necessary.  Furthermore, several metabolites were 
consistently downregulated including glutaimine, deoxyribose and methionine.  
Investigation of these metabolites may lead to novel discoveries involving the role of 





Table 2.2: Z-scores for metabolites across four ALCL cell lines. (z>1, red.  z<-1, green) 
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Based on the complexity of the data and the differences between cell lines, 
we chose to focus subsequent studies on SU-DHL-1 since to showed the greatest 
extent of ALK metabolic regulation (Figure 2.6A).   Of the 4784 mass spectral 
features identified, 502 represented known chemical structures. Unsupervised 
hierarchical clustering of all mass spectral features revealed a high degree of 
reproducibility within the replicates and demonstrated a distinct metabolic signature 
associated with NPM-ALK activity (Figure 2.8A).  Supervised clustering using those 
mass spectral features that showed a change with p < 0.1, representing 1284 mass 
spectral features, revealed a subset of metabolites that decreased (524 mass 
spectral features) as well as  increased (758 mass spectral features) in response to 




Figure 2.8:   Hierarchical clustering of SU-DHL-1 metabolomics data.  (A) Unsupervised 
hierarchical clustering of all identified mass spectral features in DMSO and CEP treated 
cells (D1-D4 are DMSO samples, C1-C4 are CEP samples).  B) Supervised hierarchical 






To determine the metabolic pathways which were significantly altered by 
NPM-ALK, we utilized MetaboAnalyst 2.0245,246 to assess the pathway enrichment 
within our metabolomic dataset.  Pathways were ranked based on two dimensions of 
significance: a p-value based on metabolite set enrichment analysis (MSEA) and a 
pathway impact score based on the centrality of the identified metabolites within the 
directional network.  Figure 2.9 shows the results of the MetaboAnalyst analysis with 
each circle representing a distinct metabolic pathway that is altered by NPM-ALK.  
The size and color of the circles corresponds to the impact score and the –log(p) 
values respectively.  In order to derive a list of significant pathways from this two-
dimensional plot, we assigned a statistical cutoff at y>1/x (y=-log(p), x=impact 
score).  This cutoff allowed for the exclusion of pathways with either low -log(p) 
values or low pathway impact scores.  Metabolic pathways whose –log(p) value and 
pathway impact score exceed this threshold were considered to be significantly 
altered by NPM-ALK signaling.  The pathways that met the statistical criteria were 
ranked by –log(p) value in Figure 2.10.  These results showed significant changes in 
a number of pathways involved in biomass production, including purine metabolism 
(p<0.01) pyrimidine metabolism (p<0.01), glycerophospholipid metabolism (p<0.01), 
and glycine, serine and threonine metabolism (p<0.01).  Importantly, pathways 
affecting  glycolysis (p<0.01), the pentose phosphate shunt (p<0.01), and the 
tricarboxylic acid (TCA) cycle (p<0.01) which serve as the starting point for many 
biomass producing pathways involved in the Warburg effect193 were also 







Figure 2.9:  Metabolomic pathway analysis using MetaboAnalyst 2.0.  Data output from 
pathway analysis (DMSO vs. CEP).  Pathways represented as colored circles.  P value is 
assigned based on the coverage and change observed in a given metabolic pathway.  A 
pathway impact score was assigned based on the location of the identified metabolites in a 





Pyrimidine metabolism ranked third in p-value significance and had the 
highest pathway impact score (Figure 2.9 and 2.10).  Figure 2.11A shows the 
network diagram of pyrimidine metabolism generated by MetaboAnalyst 2.0.  The 
boxes colored in a spectrum from pale yellow to dark red represent metabolites that 
were identified by the metabolomics profiling, while blue boxes represent 
metabolites in pyrimidine metabolism that were not identified.  The intensity of the 
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Figure 2.10:  Metabolomic pathway analysis reveals changes in key biomass producing 
pathways.  Metabolanaylst 2.0 generated pathways that changed in response to ALK 
inhibition.  Only those pathways that meet the statistical cutoff described in Figure 2.9 are 






red color corresponds to the level of significance of change in metabolite in response 
to NPM-ALK inhibition (see color scale).  Four of the metabolites that changed are 
shown in the boxed insets and include cytidine that increased in response to NPM-
ALK inhibition and cytosine, orotate and (S)-dihydroorotate which decreased in 
response to ALK inhibition (Figure 2.11A).  Many of the metabolites in this pathway 
were identified with highly significant change in response to NPM-ALK inhibition 
suggesting that NPM-ALK plays a critical role in the regulation of nucleotide 







Figure 2.11:  Metabolomic pathway analysis shows significant changes in pyrimidine 
metabolism. (A) Network diagram for components of pyrimidine metabolism that were 
altered by ALK.  The identified metabolites are colored yellow to red according to the 
significance of change following ALK inhibition (see color scale).  Boxed insets represent a 
subset of metabolites that were changed in response to ALK inhibition (in normalized 
concentrations).  (B) Network diagram for linoleic metabolism. 
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As an illustrative example of the pathway impact score, the network diagram 
for linoleic metabolism is shown in Figure 2.11B.  Linoleic metabolism generated a 
high impact score of 0.66 while the –log(p) was very low (0.47) (Figure 2.9).  Only 
one metabolite was identified in linoleic metabolism (red box), however it exists in a 
critical location within the network (Figure 2.11B).  The impact score ranks pathways 
based on the presence of these critical nodes.  Conceptually, if a node with a high 
level of out-degree centrality (the number of edges derived from a given node) is 
changed in the analysis, the impact to the entire metabolic pathway would be high.  
Therefore, linoleic metabolism received a high pathway impact score but a low p-
value (based on the lack of pathway coverage identified). 
Metabolomics datasets offer a level of complexity and limitation that 
proteomics data does not.  Specifically, while every mass spectral feature identified 
in a proteomics study can be sequenced and mapped to a protein, not all mass 
spectral features representing metabolites can be named.  This depends on the 
depth of the library for matching mass spectral features to standards within the 
library of metabolites.  Since the GSEA takes pathway coverage into account, we 
wanted to validate these results to test whether the pathway analysis we employed 
was not biased to the number of known metabolites identified  To accomplish this we 
repeated the analysis using control vs. control (DMSO vs. DMSO) (Figure 2.12A).  
This allowed us to test the outcome with a dataset that shows no significant 
metabolite changes but represents the same coverage of metabolites per pathway.  
Since the pathway impact score is based on the location of an identified metabolite 
within the network, these values were not changed in the control vs. control analysis.  
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However, since none of the metabolites significantly changed, the p-values were 
dramatically lowered (see y-axis and color scale) with the most significant pathway 
having a p-value of 0.25.  To further illustrate this point, the average –log(p) values 
for each analysis are plotted in Figure 2.12B.  The average –log(p) for the DMSO vs. 
CEP analysis was well above the p=0.05 threshold showing that many metabolic 
pathways are significantly changed.  However, the average for the control analysis is 
well below this threshold with no pathways yielding a significant p value.  The results 
provide confidence in the original analysis (Figure 2.9) showing that NPM-ALK 








Figure 2.12:  MetaboAnalyst 2.0 validation by DMSO vs. DMSO analysis  (A) Data output 
from control pathway analysis (DMSO vs. DMSO).  Color scale defines p-value.  (B) The 
average –log(p) values for all pathways in Figure 2.9 and (B) were calculated and graphed.  
The standard significance cutoff (p=0.05) is highlighted. 
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Table 2.3 provides a list of the metabolites that were regulated by NPM-ALK 
using a statistical cutoff of p<0.1 based on analysis of four biological replicates of 
DMSO and CEP treated cells.  Quantity of metabolite levels were obtained from 
normalized area under the curve (AUC) analysis from mass spectrometry.  
Importantly, we identified changes in metabolites within the significant pathways 
highlighted by pathway analysis (Figure 2.9).  Specifically, many metabolites in 
pyrimidine and purine metabolism showed an increase following NPM-ALK inhibition 
(cytidine, deoxycytidine, guanine) whereas others decreased (S-dihydroorotate, 
cytosine, ADP-ribose).  Additional significant changes were seen in the pentose 
phosphate pathway, glycolysis and fatty acid metabolism as seen by changes in 






Table 2.3: Metabolomic results for NPM-ALK regulated metabolites.  
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MetaboAnalyst was also used to compare the metabolic pathway analysis 
amongst the other ALCL cell lines used in the metabolomics study.  Table 2.4 shows 
the p-values for several of the key biomass producing pathways across 3 NPM-
ALK+ ALCL-derived cell lines.  The significant pathways are highlighted in red.  SU-
DHL-1 cells show a high degree in all of the metabolic pathways listed.  SUPM2 
cells show a similar level of significance across these biomass producing pathways 
with purine metabolism, pyrimidine metabolism, pentose phosphate pathway and the 
TCA cycle significantly altered by NPM-ALK activity.  However, DEL cells showed far 
fewer significant pathway alterations following NPM-ALK inhibition, with pyrimidine 
metabolism being the only one under the p<0.05 cutoff.  This difference between 
ALCL cells in response to CEP treatment could be a result of unknown secondary 
genetic mutations and/or differences in the efficacy of the CEP compound in the 
different cell lines. 
 
  
Table 2.4:  MetaboAnalyst pathway p-values (p<0.05, red)  
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Integrated analysis reveals NPM-ALK-regulated metabolic signature 
We integrated the phosphoproteomic and metabolomic data sets in order to 
generate a global and unified view of the NPM-ALK-regulated metabolic signature.  
We utilized the Kyoto Encyclopedia of Genes and Genomes (KEGG) mapping tools 
to integrate our phosphoproteomic and metabolomic data sets into the human 
metabolic reference map (hsa01100)247,248.  As shown in Figure 2.13, each colored 
edge represents a metabolic reaction carried out by phosphoproteins (pY, pS and 
pT) that was regulated by NPM-ALK.  Each node represents a metabolite whose 
concentration was changed after NPM-ALK inhibition (green = down, red = up).  
There were concurrent changes in both metabolites and proteins in glycolysis, the 
TCA cycle, and nucleotide biosynthesis pathways suggesting that NPM-ALK 
modulates metabolite levels in a number of pathways by altering the expression of 
phosphoproteins. 
A more detailed view of the integrated phosphoproteomic and metabolomic 
data representing components of the glycolytic pathway and pyrimidine metabolism 
are shown using KEGG’s Search&Color Pathway analysis (Figures 2.14 and 2.15).  
The colored rectangular boxes and circles represent differentially expressed 
phosphoproteins and metabolites respectively.  The color and intensity is reflective 
of the degree and direction of change following NPM-ALK inhibition, with red 
representing an increase and green representing a decrease.  Figure 2.14 illustrates 
the glycolytic pathway while Figure 2.15 shows the pyrimidine metabolism pathway 
which indicates that many components of the glycolytic and pyrimidine metabolism 
pathways are differentially regulated by NPM-ALK.  Notably, the phosphorylation of 
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many enzymes within glycolysis was decreased (green rectangular boxes) following 
ALK inhibition.  The changes in phosphoproteins and metabolites observed in 
response to ALK inhibition are shown in Tables 2.1 and 2.3 respectively.  
Specifically, Enolase (ENO1) and phosphofructokinase, liver (PFKL) showed a 
merged spectral count (pY) reduction of 30 and 6 spectral counts, respectively 
following ALK inhibition.  Both lactate (Table 2.3) and phosphorylated lactate 
dehydrogenase (LDH) (Table 2.1) decreased in response to ALK inhibition.  Lactate 
decreased with an average fold change of 0.24 and LDHB decreased with a merged 
pY spectral count change of -14. These data suggest that NPM-ALK regulates 
widespread changes in glycolysis, pentose phosphate pathway and pyrimidine 











































































































































































































































































































































































































































Figure 2.14:  Integrated “omic” analysis of glycolysis.  KEGG Search&Color Pathway 
Mapper was used to a generate pathway map of glycolysis for the proteins whose 
phosphorylation changed in response to NPM-ALK inhibition from the phosphoproteomic 
studies.  The proteomics data represents the merged pS/T (MOAC) and pY (pY-IP) 
datasets from one biological replicate of SU-DHL-1 cells.  The proteins identified are 
represented by the green and red rectangular boxes.  Green represents decrease and red 
represents increase in phosphoprotein spectral counts following NPM-ALK inhibition.  
The color intensity of the box corresponds to the extent of change.  The metabolomics 
data was integrated onto these maps and are represented as circles.  Color and intensity 
of the circles follow the same parameters as the boxes. 
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Figure 2.14:  Integrated “omic” analysis of glycolysis.  KEGG Search&Color Pathway Mapper 
was used to a generate pathway map of glycolysis for the proteins whose phosphorylation 
changed in response to NPM-ALK inhibition from the phosphoproteomic studies.  The 
proteomics data represents the merged pS/T (MOAC) and pY (pY-IP) datasets from one 
biological replicate of SU-DHL-1 cells.  The proteins identified are represented by the green 
and red rectangular boxes.  Green represents decrease and red represents increase in 
phosphoprotein spectral counts following NPM-ALK inhibition.  The color intensity of the box 
corresponds to the extent of change.  The metabolomics data was integrated onto these 
maps and are represented as circles.  Color and intensity of the circles follow the same 



















































































































































































































































































































































































































































































































Metabolic flux analysis reveals NPM-ALK-regulated metabolic shift   
Phosphoproteomic and metabolomic profiling highlighted global changes 
reflecting NPM-ALK induced steady state alterations in cellular metabolism.  
Specifically, the metabolomic analysis showed significant reduction in lactate (21.4% 
SD ± 5.6% of control, p<0.01) following NPM-ALK inhibition using area under the 
curve calculation to determine abundance (Figure 2.16), suggesting that NPM-ALK 
drives increased lactate production.   
 
 
All of the metabolomic data to this point represents a snapshot of steady state 
metabolite levels and does not provide information regarding flux through metabolic 
pathways.  Metabolism is a very dynamic process and to understand how the cells 
are utilizing the available nutrients is necessary for understanding their metabolic 
Figure 2.16:  NPM-ALK activity drives lactate production.  (A)  Quantitation of lactate levels 
from the metabolomics analysis.  Representative spectra for DMSO (Blue) and CEP (Red) 
treated cells.  (B) The quantitation of lactate based on four replicates.  **p<0.01 
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demands.  To address this question we investigated the kinetics of glucose 
metabolism by determining the flux of glucose carbons through different metabolic 
pathways. ALCL-derived cell lines were cultured in 13C-glucose and exposed to the 
ALK inhibitor.  [13C]-isotopomers of various metabolites were determined by LC-MS.  
After 30 minutes of growth in [U-13C]-glucose, the majority of the lactate appeared as 
fully labeled [m+3] demonstrating that it was derived directly from glucose (Figure 
2.17A).  Interestingly, NPM-ALK inhibition resulted in a significant reduction (52 ± 
19% of control, p<0.05) of glycolytic flux to lactate.  Similarly, flux of other key 
metabolites was also impacted by NPM-ALK.  Glucose flux to glucose 6-
phosphate+fructose 6-phosphate (G6P+F6P) showed a significant reduction (63% of 
control, p<0.01) following NPM-ALK inhibition (Figure 2.17B).  Since generation of 
G6P from glucose represents the first step in glycolysis after glucose entry into the 
cell, the reduced flux to G6P can be attributed to a reduced glucose uptake rate.  
Similarly 6-labeled [m+6] fructose 1,6 bisphosphate (FBP) and 3 labeled [m+3] 
phosphoenolpyruvate (PEP) were also significantly reduced following NPM-ALK 
inhibition (79% of control, p<0.05) (Figure 2.17C-D).  Since FBP is an intermediate 
metabolite and PEP is toward the end of glycolysis, this indicates that NPM-ALK 
regulates glycolytic flux.   
Interestingly, ribose 5-phosphate+xylose 5-phosphate (R5P+X5P) which are 
key metabolites within the pentose phosphate shunt and supply the sugar backbone 
for nucleotide biosynthesis  also showed a significant reduction of m+5 labeling after 
NPM-ALK inhibition (61% of control, p<0.01) (Figure 2.17E).   These data indicate 
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that NPM-ALK activity increases the flux of glucose metabolism and the pentose 
phosphate shunt favoring pathways that lead to biomass synthesis.   
Importantly, when total pools (all 13C labeled and unlabeled species 
combined) of ADP and ATP were evaluated after NPM-ALK inhibition, a shift in 
energy balance was observed.  NPM-ALK inhibition induced a 133% (SD ± 33%, 
p<0.01) increase in ATP levels while reducing ADP levels by 72% (SD ± 33%, 
p<0.01) (Figure 2.17F).  These data suggest that ALK activity results in a metabolic 
shift away from energy production favoring biomass production.  Importantly, ATP 
levels are often used as a surrogate for cell health and viability249.  Thus, the 
resulting decrease in glycolytic flux in response to NPM-ALK inhibition is not 
attributable to a loss in viability, but represents a metabolic shift toward energy 







Figure 2.17:  Metabolic flux analysis reveals NPM-ALK driven shift toward biomass 
production.  (A) Metabolic flux analysis of lactate in SU-DHL-1 cells following 300nM CEP 
treatment and 30 minutes treatment with 
13
C-glucose.  All species of labeled lactate are 
shown. Mass = m.   Flux analysis for fully labeled glucose 6-phosphate/fructose 6-phosphate 
(G6P/F6P) (B), fructose bisphosphate (FBP) (C), phosphoenolpyruvate (D), and ribose 5-
phosphate/xylose 5-phosphate (R5P/X5P) (E) are shown in the presence of DMSO or ALK 
inhibitor.    (F) Total pool abundance (all labeled and unlabeled species combined) for ADP 




In order to quantify NPM-ALK induced changes in metabolic reprogramming 
for subsequent studies, we measured ATP and lactate levels using biochemical 
assays.  A significant decrease in lactate was detected after ALK inhibition in two 
ALCL-derived cell lines (18% (SD ± 2.6%, p<0.01) decrease in DEL cells and 35% 
(SD ± 2.9%, p<0.01) in SU-DHL-1 cells).  There was an increase in ATP levels after 
ALK inhibition in both DEL (15% (SD ± 4.3%, p<0.05) and SU-DHL-1 cells (48% (SD 
± 5.9%, p<0.01), while no changes in lactate or ATP levels were observed in Jurkat 
(ALK negative T-cell leukemia) cells (Figure 2.18).  Taken together, these data 
highlight a metabolic shift driven by ALK characterized by an increase in biomass 




Figure 2.18:  NPM-ALK drives metabolic shift away from energy production. Biochemical 
assays for Lactate (from conditioned media) and ATP (from cell lysates) after 300 nM CEP for 




Integrated analysis of the phosphoproteomic and metabolomic data identified 
a novel role of NPM-ALK in the regulation of cellular metabolism.  Proteins and 
metabolites within glycolysis, the pentose phosphate shunt, and pyrimidine 
metabolic pathways were significantly regulated by the tyrosine kinase activity of 
NPM-ALK.   The observations indicate that oncogenic signaling of NPM-ALK results 
in an increase in biomass production by re-routing glycolytic intermediates.  Our 
studies represent the first to integrate these powerful screening tools to address the 
question of metabolic regulation by an oncogenic kinase. 
While we were able to identify key metabolic characteristics of ALK kinase 
activity, this study also points out the limitations of utilizing and integrating large-
scale datasets.  First, the tools to conduct this level of integration (metabolite and 
protein phosphorylation) are very limited.  Also, the complexity of the data and the 
variability between cell lines yield difficulties in funneling the data into clear and 
concise conclusions. 
We were able to identify key metabolic and protein phosphorylation changes 
in numerous biomass producing pathways and map these changes on the KEGG 
metabolic pathway maps.  However, the final interpretation of these landscape 
images must be considered in the context of the role of each protein 
phosphorylation.  While, several glycolytic proteins are known to be phosphorylated 
and this phosphorylation alters the enzymatic activity198,214,218,250,251, many of the 
phosphorylation sites we identified are novel and may play an activating or inhibitory 
94 
 
role.  Therefore, to gain a complete understanding of the metabolic signature of ALK 
expression, investigation of each protein phosphorylation is necessary. 
Phosphoproteomic and metabolomic analysis also indicated that lipid 
metabolism, amino acid metabolism and nucleotide synthesis metabolism were 
regulated by NPM-ALK. (Table S1 and S2).   Tyrosine phosphorylation or 
transcriptional regulation of key metabolic enzymes involved in these pathways such 
as lactate dehydrogenase A (LDHA)209,218, mitochondrial pyruvate dehydrogenase 
kinase 1 (PDHK1)250, phosphoglycerate mutase 1 (PGAM1)216, have been 
implicated in mediating an oncogenic metabolic switch.  Furthermore, recent studies 
highlighting the importance of citrate metabolism or impaired TCA cycle function in 
cancer cells support the notion that metabolic adaption is a hallmark of 
oncogenesis252.  Accordingly, future studies to elucidate the molecular mechanisms 
underlying ALK-dependent regulation of proteins and metabolites within lipid 
metabolism, nucleotide synthesis and amino acid metabolism are warranted.   
Our metabolomic studies identified significant changes in glycine, serine and 
threonine metabolism in response to ALK inhibition (Figure 2A).  Recent studies 
have demonstrated that PKM2 may regulate de novo serine synthesis from the 
glycolytic intermediate 3-phosphoglycerate (3-PG)226,253.  The amino acid serine 
contributes to increased cellular biomass as well as the activation of mTORC1253.  
Given the previously demonstrated effect of NPM-ALK in the activation of 
mTORC1165, our results provide a potential link between NPM-ALK and serine 





 The generation and integration of the phosphoproteomic and metabolomic 
data led to novel discoveries regarding the role of NPM-ALK in the regulation of 
cellular metabolism.  These large-scale datasets serve as unique resources for the 
identification of novel ALK substrates.  The subsequent chapters (3 and 4) utilize the 
data obtained through phosphorylation and metabolic analysis to identify novel 
substrates of ALK and pursue the in depth biochemical and biological consequence 
of this relationship.  However, these datasets provide a rich opportunity to discover 
additional important signaling mechanisms driven by ALK that are not covered in this 
dissertation.   
Specifically, the role of ALK signaling in regulating glutamine metabolism is 
unknown.  Through our metabolomics analysis we identified glutamine 
concentrations to be altered upon ALK inhibition in all of our ALCL cell lines (Table 
2.2).  Glutamine metabolism plays an important role in mediating biomass 
production and the Warburg effect through c-Myc activation254.  Since NPM-ALK is 
known to activate c-Myc124, it is likely that NPM-ALK signaling also results in 
alterations within glutamine metabolism to drive the Warburg effect. 
Additionally, the integrated analysis revealed alterations in lipid metabolism 
that were regulated by ALK.  Specifically, ALK was found to regulate ACLY through 
our phosphoproteomic analysis (Table 2.1).  Additionally, the metabolomic analysis 
reveals changes in several lipid metabolism components (Table 2.3).  Since cancer 
96 
 
cells must double their membrane size in order to progress through mitosis, the 
generation of lipids is a metabolic priority255.  A future project could use these data 
as rationale for exploring the mechanisms behind ALK regulated lipid metabolism, 









NPM-ALK Phosphorylates PKM2 Resulting in Metabolic Reprogramming and 
Increased Tumorigenesis 
ABSTRACT 
The integrated phosphoproteomic and metabolomic studies identified an 
NPM-ALK mediated metabolic shift.  We identified ALK regulated changes in 
glycolysis and its derivative biomass producing pathways.  We also identified PKM2 
to be differentially phosphorylated upon ALK inhibition.  Therefore, we hypothesized 
that NPM-ALK regulates the metabolic shift through the phosphorylation of PKM2.  
NPM-ALK was found to directly phosphorylate PKM2 at the Y105 residue which 
consequently reduced its enzymatic activity.  Small molecule activation of PKM2 or 
expression of an Y105F PKM2 mutant led to reversal of the metabolic switch with 
increased oxidative phosphorylation and reduced lactate production.  Increased 
PKM2 activity and decreased phosphorylation resulted in decreased lymphoma cell 
viability, colony formation and reduced tumor growth in an in vivo xenograft model.  
Our studies show that PKM2 is a novel substrate of NPM-ALK and plays a critical 
role in mediating the metabolic shift towards biomass production and tumorigenesis.  





 Global metabolic changes that coordinated with phosphoproteomic changes 
were characteristic of NPM-ALK expression and activity (Chapter 2).  Many of these 
metabolic and proteomic changes were centered on glycolysis and its derivative 
biomass producing pathways (the pentose phosphate pathway, pyrimidine 
metabolism, and purine metabolism).  Interrogation of these data led to the 
identification of PKM2 as a novel mediator of NPM-ALK signaling and a candidate 
effector molecule in the metabolic phenotype orchestrated by NPM-ALK. 
 PKM2 has been implicated in the Warburg effect and has been shown to be 
necessary for tumorigenesis256.  Through differential splicing mechanisms PKM2 
becomes the predominate PK isoform in proliferating cells257.  Expression of the 
PKM2 isoform over the PKM1 isoform allows for the regulation of the last step in 
glycolysis.  Phosphorylation of PKM2 as well as the lack of binding of the allosteric 
activator fructose bisphosphate (FBP) results in dimerization and loss of activity214.  
The inactivity of PK at the end of glycolysis coupled with the general increase in 
glucose uptake and glycolytic flux seen in many cancer cells, results in the backup of 
the glycolytic intermediates that serve as starting material for biomass production190.  
Another result of this metabolic reprogramming is the increased lactate production 
which is necessary to maintain redox balance when driving a metabolism based 
mainly on glycolysis. 
We hypothesized that NPM-ALK phosphorylates PKM2 at Y105 to drive the 
metabolic shift observed in Chapter 2.  The objective of this study was to 
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characterize the functional relationship of NPM-ALK and PKM2 as well as to 
determine the role of PKM2 in ALCL tumorigenesis.  This study identified PKM2 as a 
novel substrate of NPM-ALK and that mediated the Warburg effect in NPM-ALK+ 
ALCL.  We showed that NPM-ALK directly phosphorylates PKM2 at Y105 and 
caused a decrease in its enzymatic activity.  Small molecule activators of PKM2 or 
expression of a PKM2 mutant (Y105F PKM2) resulted in a reversal of the NPM-ALK 
induced metabolic shift and decreased tumorigenesis of NPM-ALK+ ALCL cells.  
These studies reveal a novel role of NPM-ALK in the regulation of cellular 
metabolism via the phosphorylation of PKM2 and offer a rationale for PKM2 
activators as potential therapeutic agents for NPM-ALK+ ALCL. 
MATERIALS AND METHODS  
Cell Lines:  Stable PKM2 expressing cell lines were generated with lentiviral 
transduction from 293FT transfected cell cultured media. Viral packaging plasmid 
psPAX2 and envelope plasmid pMD2.G were used to generate viral particles while 
PKM2 was cloned into pRSV-Puro with an N-terminal Flag tag.  Stable cell lines 
were established with puromycin selection. 
Western Blotting:  Proteins from cell lysates were extracted with lysis buffer (25 mM 
Tris-Base, 2% SDS, pH 7.4) followed by sonication and centrifugations (16,000 rpm 
for 10 min).  Protein concentrations were determined by BCA assay (Thermo 
Scientific, Rockford, IL).  Twenty μl of protein was separated by SDS-PAGE and 
transferred to nitrocellulose membranes.  Western blotting was performed using the 
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following antibodies: ALK (Invitrogen, Carlsbad, CA), pY1604-ALK, PKM2 and 
pY105-PKM2 (Cell Signaling Technologies, Danvers, MA). 
In vitro kinase assay:  GFP-tagged WT NPM-ALK and K210R NPM-ALK were 
transfected in 293T cells using lipofectamine 2000 (Invitrogen, Carlsbad, CA) and 
cells were lysed 48 hours later.  Immunoprecipitation using GFP antibody and 
Protein A/G agarose beads was used to purify NPM-ALK.  His-tagged full-length 
PKM2 (WT, Y105F and Y390F) were expressed in E. coli using isopropyl β-D-1-
thiogalactopyranoside (IPTG) induction.  Proteins were purified using Ni-
nitrilotriacetic acid (NTA) resin, washed 5 times and eluted with 250 mM imidazole 
(pH 8.0).  PKM2 elution was added to NPM-ALK agarose beads along with 10X 
kinase buffer and 10 mM ATP.  Following 30 minute incubation at room temperature, 
6X laemmli buffer was added and the samples were boiled for 5 minutes.  The 
reactions were then loaded onto and SDS-PAGE gel and western blots were 
performed. 
PKM2 Activity:  PKM2 activity assays were performed as previously described214.  
Briefly, cell lysates (source of PKM2) were incubated with 1mM ADP, 0.5 mM PEP, 
0.3 mM NADH and 8 U of LDH.  The kinetics of oxidation of NADH is measured by 
absorbance at 340 nm every 5 minutes until completion of reaction.  The slope of the 
decrease in absorbance was calculated by linear regression analysis and reported 
as PKM2 activity. 
Metabolic Assays:  Lactate and ATP was measured in conditioned media and cell 
lysates, respectively using commercially available kits (BioVision, Milpitas, CA).  Cell 
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lysates were used for ATP analysis and conditioned culture media was used for 
lactate measurements.   
Proliferation and Colony Formation Assays:  Proliferation was determined by trypan 
blue stain and measured on the TC10 Automated Cell Counter (Bio-Rad, Hercules, 
CA).  Cells were seeded at 50,000 cells/ml on day 0.  Colony formation assays were 
performed with Methocult H4230 (Vancouver, BC) per manufactures instructions.  
Colonies were grown for 14 days before staining with p-iodonitrotetrazolium chloride 
(Sigma-Aldrich, St. Louis, MO).  Initial seeding density was 200 cells/ml. 
Xenograft Experiments:  Shaved (severe combined immune-deficient) SCID-Biege 
mice (Charles River, Wilmington, MA) were injected (using 27G needle) with 6 
million cells in the subcutaneous flank.  100 μl injection volume containing 50% BD 
Matrigel (BD, San Jose, CA) was used.  Tumors were measured with calipers and 
the tumor volumes determined through the following equation:  V = (0.5)*(L*W2).  
During necropsy, tumors were divided for protein extracts and histology.  Samples 
for protein extracts were flash frozen in LN2, ground into a powder and stored at -
80°C.  Samples for histology were fixed in 10% formalin.  Samples were paraffin 





PKM2 is a substrate of NPM-ALK 
Based on the integrated proteomic/metabolomic analysis (Chapter 2) and the 
results of the metabolic flux analysis which demonstrated the effect of ALK on 
glycolysis, we pursued the hypothesis that the NPM-ALK directed changes in cellular 
metabolism were mediated through phosphorylation of PKM2. Our 
phosphoproteomic analysis identified phospho-PKM2 (p-PKM2) to be significantly 
reduced following ALK inhibition (z=-1.1) (Figure 2.4).  The MS data showed two 
unique tyrosine phosphorylated peptides of PKM2 decreased upon NPM-ALK 
inhibition (the peptides contained Y105 and Y390).  The representative tandem 
mass spectra for the peptides containing pY105 (Figure 3.1A) and pY390 (Figure 
3.1D) PKM2 are shown.  Both peptides were identified with an adjusted probability 
greater than 0.99.  The adjusted probability reflects the probability that the identified 






Figure 3.1:  Mass spectrometry identification of phosphorylated PKM2.  (A)  A 
representative tandem mass spectrum of the PKM2 peptide containing the pY105 residue.  
(B) A representative tandem mass spectrum of the PKM2 peptide containing the pY390 
residue.  Identified b and y ions are indicated. 
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Figure 3.2A tabulates the spectral counts of phosphopeptides of ALK and 
PKM2 that were determined in a representative experiment in which SU-DHL-1 cells 
were exposed to DMSO or CEP.    There was a significant reduction of spectral 
counts of ALK-derived phospho-Tyr peptides (76 in DMSO to 0 in CEP), suggesting 
that the CEP treatment was effective at inhibiting ALK autophosphorylation.  
Similarly, the spectral counts for peptides containing pY105 PKM2 were reduced 
from 9 (DMSO) to 2 (CEP treated), while those for the pY390 residue were reduced 
from 3 to 1.  These data provided the rationale to pursue subsequent studies to 
characterize PKM2 as a mediator of ALK-regulated switch in cellular metabolism.  
Given the role for pY105-PKM2 in the regulation of its enzymatic activity, we decided 
to pursue this residue in subsequent studies in NPM-ALK+ ALCL cell lines. 
Additionally, we analyzed nine T-cell lymphoma derived cell lines using 
phosphoproteomic analysis, the results of which are provided in Figure 3.2B.  
Phosphorylated peptides derived from PKM2 were identified in all four of the ALK+ 
ALCL cell lines as well as the natural killer/T-cell lymphomas (NK/T-NHL) but not in 
the ALK negative ALCL (ALK- ALCL), Sézary syndrome (SS) and mycosis fungoides 
(MF) cells.  Western blot analysis corroborated the proteomic results and revealed 
that the levels of pY105-PKM2 were highest in the ALK+ ALCL cell lines (SU-DHl-1, 
SUPM2 and Karpas299) and the YT cell line while the rest of the cell lines 
expressed negligible levels of pY105-PKM2 (Figure 3.2C).  In contrast, there was no 
difference in the expression of total PKM2 or GAPDH.    These data indicate that 






Figure 3.2:  pY105-PKM2 is regulated by NPM-ALK and shows differential expression across 
other T-cell derived lymphoma.  (A) Spectral count changes in p-ALK (all phosphorylated 
peptides) and the two identified PKM2 phosphopeptides in response to NPM-ALK inhibition.  
(B)  Phosphoproteomic data from nine different T-cell lymphoma derived cell lines.  Data 
shows the number of peptides and the spec counts for the identification of PKM2 across the 
different disease entities.  C)  Western blot analysis of different T-cell lymphoma derived cell 
lines for phosphorylated and total PKM2.  Mycosis fungoides (MF), Sézary syndrome (SS), 
Natural killer/T-cell lymphoma (NKTL). 
106 
 
To confirm the phosphoproteomic data suggesting that pY105-PKM2 is 
regulated by NPM-ALK, western blot analysis of ALCL-derived cells were performed 
in the presence of DMSO or CEP (Figure 3.3A).  CEP treatment (6hrs, 300nM) 
resulted in inhibition of ALK (as evidenced by abrogation of pY1604 ALK) and a 
marked reduction of pY105-PKM2 (56% of control) without a change in total PKM2.   
To verify that these effects are not cell line dependent or a result of selectivity of the 
CEP compound, we utilized another specific inhibitor of ALK (Crizotinib)181 in two 
additional ALCL-derived cell lines.  Crizotinib treatment for 16 hours resulted in a 
significant decrease in Y105 phosphorylation of PKM2 in a dose dependent manner 
(Figure 3.3B).  Crizotinib (100nM) resulted in reduction of pY105-PKM2 levels to 
53% and 24% of control in SUPM2 and DEL cells, respectively, while 300nM 
Crizotinib reduced the levels of pY105-PKM2 to 62% and 15% of control.  
Furthermore, transfection of 293T cells with WT NPM-ALK resulted in an increase in 
Y105 PKM2 (average 140%) compared to those transfected with a kinase deficient 
mutant, K210R NPM-ALK (Figure 3.3C).  These results suggest that the kinase 
activity of NPM-ALK regulates the phosphorylation of PKM2 at the Y105 residue. 
Additionally, BA/F3 cells stably transfected with either empty vector (EV) or 
WT NPM-ALK were analyzed for pY105-PKM2 levels via western blotting.  BA/F3 
cells are a murine pre-B-cell line that is IL-3 growth dependent258.  This is a powerful 
model for determining the transforming potential of oncogenes, as NPM-ALK 
expression is able to make these cells IL-3 independent235.  Figure 3.3D shows that 
pY105-PKM2 was present in both EV and WT NPM-ALK conditions under the 
presence of IL-3.  Upon removal of IL-3 the pY105 was lost from PKM2 in a time 
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dependent manner in the EV expressing cells (44% after 4 hours).  However, WT 
NPM-ALK expression stabilized pY105 levels of PKM2 with no loss of signal after 4 
hours of IL-3 removal.  These data suggest that NPM-ALK (and possibly IL-3) 
regulates the phosphorylation of Y105-PKM2. 
In order to determine whether PKM2 is a direct substrate of NPM-ALK kinase 
activity and not a distant downstream signaling molecule, we carried out in vitro 
kinase assays using immunoaffinity-purified WT or K210R GFP-NPM-ALK and His-
tagged WT, Y105F and Y390F PKM2 purified from E. coli.  After incubation of both 
proteins with ATP, western blot analysis was used to detect pY105-PKM2 (Figure 
3.3E).  Since NPM-ALK is capable of autophosphorylation, pY1604-ALK was used 
as a positive control.  As shown in Figure 3.3D, WT NPM-ALK was 
autophosphorylated in contrast to the K210R NPM-ALK mutant which showed no p-
ALK.  WT PKM2 was phosphorylated at the Y105 residue in the presence of active 
NPM-ALK, but not when it was incubated with K210R NPM-ALK.  Also, pY105-
PKM2 was not detected when Y105F PKM2 was incubated with WT NPM-ALK.  The 
Y390F PKM2 mutant was also phosphorylated at the Y105 residue by WT NPM-
ALK.  These data show that NPM-ALK directly phosphorylates PKM2 at the Y105 







Figure 3.3:  NPM-ALK directly phosphorylates pY105-PKM2.  (A)  Immunoblots of lysates 
from SU-DHL-1 cells following CEP treatment for 6hrs at 300nM CEP.  (B) Immunoblots of 
SUPM2 and DEL cell lysates after treatment with 100nM and 300nM Crizotinib for 16 hours. 
(C) Immunoblots of 293T lysates that were transiently transfected with either WT NPM-ALK 
or K210R NPM-ALK (samples in duplicate).  (D)  Immunoblots from BA/F3 cells stably 
transfected with either empty vector (EV) or WT NPM-ALK.  Cells were lysed following 0, 2 or 
4 hours of IL3 removal from media.  (E)  In vitro kinase assay with purified His-PKM2 (WT, 
Y105F or Y390F) and ALK immunoprecipitation using GFP-NPM-ALK (WT or K210R).  
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NPM-ALK regulates PKM2 activity via Y105 phosphorylation 
We next sought to determine the effect of NPM-ALK mediated 
phosphorylation of PKM2 on its enzymatic activity using an assay that measures the 
conversion of phosphoenolpyruvate (PEP) to pyruvate with subsequent LDH-
catalyzed conversion of pyruvate to lactate.  The consumption of NADH by LDH is 
measured by optical density (OD) at 340nm and the kinetics are calculated (Figure 
3.4A, schematic)214.  Based on a series of experiments to optimize the dose and 
duration, we evaluated cell lysates of ALCL cell lines to quantitate PKM2 activity 
after a 4-hour exposure to CEP (100 nM).  Figure 3.4B shows the raw kinetic data 
for this experiment.  The positive control contains purified PK, while the negative 
control contains no PK source.  The slope of the OD decay was calculated using 
linear regression analysis and is plotted at the PKM2 activity rate in Figure 3.4C.  
Inhibition of ALK resulted in a significant increase in PKM2 enzymatic activity (159% 
of control, p<0.01), suggesting that NPM-ALK reduces PKM2 activity.  Similarly, 
293T cells transfected with WT NPM-ALK showed reduction of PKM2 activity by 
14% (SD ± 2.9%) compared to mock transfected cells and those transfected with a 
kinase-deficient K210R NPM-ALK mutant (Figure 3.4D-E).  Interestingly, the levels 
of PKM2 activity correlated with the levels of Y105-PKM2 phosphorylation under 
varying NPM-ALK activity/expression conditions (Figures 3.3A and 3.3C).  These 






Figure 3.4:  NPM-ALK regulates the activity of PKM2.  (A)  Schematic representation of 
PKM2 activity assay.  PEP, ADP, NADH and LDH are added to the reaction in excess.  PKM2 is 
supplied from cell lysates.  Activity is determined by the slope of decay of 340nm optical 
absorbance.  (B)  PKM2 activity assay timecourse for SUPM2 cells treated with DMSO or CEP 
100nM for 4 hours.  Positive control contains purified PKM2 protein, negative control 
contains no PKM2.  (C)  Quantification of PKM2 activity rate from (B) by calculating slope.  
(D) PKM2 activity assay timecourse on lysates from 293T cells transfected with mock, WT 
NPM-ALK or K210R NPM-ALK. (E)  Quantification of PKM2 activity rate from (D) by 
calculating slope. Data are mean ± SD, **p<0.01 
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In order to directly evaluate the function of the pY105-PKM2 in ALK 
expressing cell lines, we generated cell lines stably expressing a non-
phosphorylatable Y105F-PKM2 mutation.  Expression of flag-Y105F-PKM2 and flag-
WT-PKM2, are shown in Figure 3.5A.  As shown in Figure 3.5B, DEL cells which 
express Y105F-PKM2 displayed increased PKM2 activity, 68% (SD ± 6%, p<0.01) 
compared to WT control.  Together, these data demonstrated that phosphorylation 
of PKM2 by NPM-ALK results in inhibition of its enzymatic activity. 
 
 
Phosphorylation of PKM2 alters cellular metabolism 
In order to assess the biological implications of NPM-ALK mediated 
phosphorylation of PKM2 and consequent inhibition of its enzymatic activity, we 
utilized two small molecule activators of PKM2 and evaluated their effect on cellular 
metabolism of ALCL-derived cell lines.  The two compounds (NCGC00186528 
Figure 3.5: pY105-PKM2 reduces its enzymatic activity.  (A) Stable expression of Flag-PKM2 
in DEL cells.  B) PKM2 activity assay of DEL cells stably expressing WT or Y105F PKM2. Data 
are mean ± SD, **p<0.01 
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(TEPP-46), and NCGC00186527 (NCGC-527)) were derived from the chemical 
class thieno-[3,2-b]pyrrole[3,2-d]pyridazinone and differ only by a change in one 
side-group (Figure 3.6A)225.  Anastasiou et al. reported the PKM2 activating 
capabilities of these compounds (Figure 3.6B).  Treatment of SU-DHL-1 cells with 30 
μM of the two activators (NCGC-527 and TEPP-46) for 16 hours, resulted in a 
significant increase, 52% (SD ±11%, p<0.01) and 57% (SD ± 11%, p<0.01) 
respectively, in PKM2 activity (Figure 3.6C).  These compounds as well as the 
Y105F-PKM2 expressing cells provided us with valuable tools to investigate the role 
of PKM2 activity and phosphorylation in NPM-ALK expressing cells. 
 
  
Figure 3.6: PKM2 activator compounds increase PKM2 enzymatic activity.  (A)  Chemical 
structures of NCGC00186527 (top) and TEPP-46 (bottom).  (B)  TEPP-46 and DASA-58 (not 
used in this dissertation) effects on PKM1 (M1) and PKM2 (M2) activity.  Data from 
collaborators (Anastasiou et al. 2012).  (C) PKM2 activity assay using SU-DHL-1 treated with 
10μM NCGC-527 or TEPP-46 for 24 hours.  Data are mean ± SD, **p<0.01 
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The activation of PKM2 by NCGC-527 led to a significant decrease in lactate 
production, 20% (SD ± 6.4%, p<0.01) in Karpas299 cells and 23% (SD ± 5.1%, 
p<0.01) in DEL cells (Figure 3.7A).  This was associated with a corresponding 
increase in ATP levels with a 67% (SD ± 12%, p<0.01) increase in Karpas299 cells 
and a 19% (SD ± 1%, P<0.01) increase in DEL cells.  Jurkat cells (ALK negative) did 
not show a significant change in lactate or ATP levels following PKM2 activation by 
either compound.  Similarly, DEL cells stably expressing Y105F-PKM2 also 
exhibited a metabolic shift compared to WT-PKM2 expressing cells (Figure 3.7B).  
The mutant Y105F-PKM2 expressing cells produced 42% (SD ± 7.7%, p<0.01) less 
lactate and 69% (SD ± 3.2%, p<0.01) more ATP than their WT counterpart.  These 
data indicate that NPM-ALK expression results in phosphorylation of PKM2 with 
consequent inhibition of its activity and altered cellular metabolism.  The metabolic 
shift, driven by NPM-ALK causes increased lactate production, a known marker of 
the Warburg effect.  Furthermore, this shift in metabolism decreases ATP production 








Phosphorylation of PKM2 regulates cell proliferation  
Next, we investigated the effect of PKM2 phosphorylation on cell proliferation.  
DEL cells were treated with increasing concentrations of PKM2 activator (NCGC-
527) and cell proliferation was monitored over 72 hours by trypan blue staining 
under both normoxic (21% O2) and hypoxic (3% O2) conditions to determine their 
sensitivity in differing oxygenated environments.  There was reduction of cell 
proliferation in a dose dependent manner in both normoxic and hypoxic conditions 
(Figure 3.8A).  At 72 hours, cells exposed to PKM2 activator NCGC-527 (30μM) 
showed a 54% (SD ± 8.6%, p<0.01) reduction in proliferation in normoxic conditions 
compared to DMSO.  At the same concentration of NCGC-527 cells in hypoxic 
conditions showed a 69% (SD ± 5%, p<0.01) reduction in proliferation.  Interestingly, 
under normoxic conditions the cells still maintained greater than 85% viability (as 
Figure 3.7: PKM2 activity and phosphorylation induce a metabolic shift. (A)  Lactate and 
ATP assays using conditioned media and cell lysates (respectively) on Karpas299, DEL and 
Jurkat cells following 6 hour treatment with 30μM NCGC-527.  C) Lactate and ATP assays on 
DEL cells stably expressing Flag-PKM2 WT on Flag-PKM2 Y105F.  
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determined by trypan blue staining) under the highest concentration of NCGC-527 
(Figure 3.8B).  In contrast, cells exposed to PKM2 activation under hypoxic 
conditions demonstrated a dose dependent decrease in cell viability with only 49% 
(SD ± 11%, p<0.01) viable cells remaining after 72 hours with 30 μM NCGC-527.  
These data suggest that chemical activation of PKM2 results in a metabolic shift 
from anaerobic glycolysis to oxidative phosphorylation.  While PKM2 activation 
decreases proliferation, it does not induce cell death under normoxic conditions.  
However, the cells grown in hypoxic conditions die as a result of PKM2 activation.  







Similarly, when DEL cells were exposed to both the PKM2 activator and 
oligomycin (ATP synthase inhibitor)259 under normoxic conditions, an additive 
decrease in cell proliferation was observed (39%, SD ± 4.7%, p<0.01 compared to 
DMSO control) (Figure 3.8C).   Furthermore, DEL cells stably expressing Y105F-
PKM2 were growth sensitive to oligomycin (72 hours) and resulted in a 30% (SD ± 
12%, p<0.05) reduction in proliferation relative to DMSO control whereas oligomycin 
had minimal effect (91% of control, SD ± 11%, p=0.2) in DEL cells stably expressing 
Figure 3.8: PKM2 regulates ALCL proliferation.  (A) Cellular proliferation measured by trypan 
blue staining of DEL cells treated with indicated concentrations of NCGC-527.  Cells were 
maintained in either normoxic or hypoxic (3% O
2
) conditions.  (B)  Viability data from (A) 72 
hour time point showing the % live cells under the indicated conditions.  (C)  Cell 
proliferation of DEL cells treated with NCGC-527, oligomycin or both (dual).  (D) Cell 
proliferation of DEL cells stably expressing Flag-PKM2 and treated with DMSO or 500nM 
oligomycin for 48 hours.  Counts were normalized to each control (DMSO) condition. Data 
are mean ± SD, *p<0.05, **p<0.01, not significant (NS) 
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WT-PKM2 (Figure 3.8D).  The increased sensitivity of Y105F-PKM2 expressing cells 
to ATP synthase inhibition suggests that these cells were more reliant on oxidative 
phosphorylation than their WT counterpart.  These data support the role for 
phosphorylation and inhibition of PKM2 as a key regulatory mechanism for the 
metabolic switch towards anaerobic glycolysis and consequent impact on cell 
proliferation. 
PKM2 regulates tumorigenesis   
To investigate the role of PKM2 in tumorigenesis of NPM-ALK+ALCL, 
methylcellulose colony formation assays were conducted using PKM2 activating 
compounds as well as WT-PKM2 and Y105F-PKM2 stably expressing DEL cells.  
Activation of PKM2 using increasing doses of NCGC-527 resulted in a significant 
reduction in number of colonies formed after 14 days in a dose response manner 
(Figure 3.9A).  The number of colonies under 10μM NCGC-527 was 107 (SD ± 7.2, 
p<0.01) which represented 24% reduction compared to DMSO treated cells.  There 
were 39% (SD ± 2.2%, p<0.01) fewer colonies in cells exposed to 30μM NCGC-527 
relative to DMSO treated cells.  Furthermore, DEL cells expressing Y105F-PKM2 
showed significantly reduced number of colonies as compared to WT-PKM2 (46%, 
SD ± 10.4%, p<0.01).  These data indicate that the activity and phosphorylation of 





In order to determine the role of PKM2 in ALK+ALCL tumorigenesis in vivo, 
we evaluated the tumorigenic potential of PKM2 activators and the WT-PKM2 and 
Y105F-PKM2 in xenografted tumors in mice.  TEPP-46 was used for this study 
based on the availability of the compound and the similarity of the in vitro effect on 
PKM2 activity and cell proliferation between NCGC-527 and TEPP-46 (Figure 3.6C 
and data not shown).  SCID-Beige mice (n=7) were implanted with DEL cells (6 
million cells per injection in 100μl injection volume containing 50% matrigel in the 
subcutaneous flank) and orally treated with either vehicle (0.5% methylcellulose + 
0.1% Tween 80) or TEPP-46 (50 mg/kg, B.I.D.) on the day of tumor injection.  Tumor 
Figure 3.9: PKM2 regulates ALCL colony formation.  (A) Methylcellulose colony formation 
assay using DEL cells treated with 10μM and 30μM NCGC-527 (A) and DEL cells stably 
expressing Flag-PKM2 WT and Y105F (B).  Samples analyzed in triplicate with a 
representative image shown below each bar.  Data are mean ± SD. *p<0.05, **p<0.01 
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volume was assessed on a daily basis until day 14 when maximal diameter 
exceeded 1cm and animals were sacrificed.  As shown in Figure 3.10A, 14 days 
after tumor injection, the vehicle treated mice showed significant tumor growth (359 
mm3, SEM ± 63 mm3) while the TEPP-46 treated mice showed marked retardation in 
tumor growth and development with mean tumor volume of 56 mm3 (SEM ± 27 mm3, 
p<0.01) with 3 of the 7 mice developing no measurable tumors.  Figure 3.10B shows 
the gross images of three representative tumors from each group of vehicle treated 
(upper panel) and TEPP-46 treated mice (lower panel).   
 
 
Figure 3.10: PKM2 regulates ALCL tumorigenesis.  (A) Tumor volumes of DEL xenograft 
tumors treated with TEPP-46 (50mg/kg, BID) by oral dose from day of tumor implantation for 
a duration of 14 days (n=7).   (B) Representative images of tumors at day 14.  (C)  Tumor 
volumes of xenografted DEL cells stably expressing WT or Y105F-PKM2 (n=5).  (D) Scatter 
plot of day 10 tumor volumes.  Data are mean ± SEM, **p<0.01 
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DEL cells stably expressing WT or Y105F PKM2 were implanted in the 
subcutaneous flank of SCID-Beige mice (n=5) and tumor volumes were measured 
over 10 days (Figure 3.10C).  Mice xenografted with cells expressing Y105F PKM2 
showed significant reduction in tumor volume compared to WT after 10 days 
(p<0.01).  The average tumor volume for the WT-PKM2 was 476 mm3 (SEM ± 64 
mm3) while the Y105F-PKM2 tumors averaged 103 mm3 (SEM ± 62 mm3) (Figure 
3.10D).   
To assess the level of exogenous Flag-PKM2 expressed in the resulting 
tumors, western blots were performed to compare expression in the implanted cells 
vs. the resulting tumors (Figure 3.11A).  Cells stably expressing WT and Y105F-
PKM2 showed strong Flag expression while the DEL parental cells did not.  Lysates 
derived from WT tumors showed Flag expression at comparable levels to the WT 
cell lines.  However, tumors in the Y105F-PKM2 group lost expression of the mutant 
PKM2 vector compared to the cell lines.  Importantly, the two Y105F-PKM2 tumors 
shown in Figure 3.11A were the only tumors in this group that were large enough to 
produce protein extracts.  These data suggest that the WT-PKM2 expression has no 
effect on tumor formation, but in Y105F-PKM2 expressing cells, tumor growth is 
contingent on the ability of these cells to lose expression of the mutant gene, as 





Furthermore, histology sections from the WT and Y105F-PKM2 expressing 
tumors were taken and stained with H&E (Figure 3.11B-C).  Tumors from both 
conditions displayed the characteristic cells of ALCL including large cells with 
abundant cytoplasm and kidney shaped nuclei.  Many mitoses were also identified in 
both conditions suggesting aggressive tumor growth.  No differences in cell size 
were observed.  Importantly, the Y105F expressing tumor (Figure 3.11C) was one of 
the two tumors large enough to take sections for histology.  Also, this tumor was 
shown to have lost expression of the Y105F-PKM2 gene (Figure 3.11A, lane 6).  
Figure 3.11:  Ex vivo analysis of PKM2 mutant tumors. (A) Western blot analysis of cell 
lines used for tumor injections and tumor lysates from several of the developed tumors 
from (Figure 3.10 C-D).  (B) H&E staining of a tumor section for WT PKM2 expressing DEL 
cells.  (C) H&E staining of a tumor section for WT PKM2 expressing DEL cells. 
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Therefore, these data substantiate the idea that the Y105F-PKM2 expressing cells 
will not undergo tumorigenesis unless the expression of this mutant gene is lost.  
The results from this study suggest that phosphorylation of PKM2 at the Y105 
residue plays a major role in promoting ALCL tumorigenesis.  Taken together, these 
data indicate that the phosphorylation and inhibition of PKM2 is an important aspect 
of NPM-ALK regulated tumorigenesis in ALCL. 
DISCUSSION 
This study reveals that PKM2 mediates the NPM-ALK directed metabolic shift 
towards a Warburg effect (Figure 3.12).  Inhibition of PKM2 via Y105 
phosphorylation reprograms the cellular metabolism to generate biomass which is 
necessary for tumorigenesis.  We show that through chemical activation of PKM2 or 
the mutation of the Y105-PKM2 residue, the cellular metabolism is diverted back to a 
more “normal” metabolism that is dependent on oxidative phosphorylation and not 
conducive to tumorigenesis. 
PKM2 is a key regulator of aerobic glycolysis.  As the last enzyme in 
glycolysis, the PKM2 isoform of pyruvate kinase is frequently expressed in tumors 
and proliferating cells256.  The enzymatic activity of PKM2 has been shown to be 
regulated by tyrosine phosphorylation and phosphorylated peptide binding214,223 with 
consequent diversion of glycolytic intermediates toward biomass production.  Our 
data provide evidence that tyrosine phosphorylation of Y105 PKM2 by NPM-ALK 
may represent a mechanism by which lymphoma cells acquire a metabolic 
advantage that facilitates tumor growth.  Pharmacological activation of PKM2 and 
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the expression of Y105F-PKM2 were effective in reversing the metabolic switch and 
subsequent proliferation and tumorigenesis.  Our data substantiates the role of 
PKM2 in metabolic reprogramming in lymphoid cells and expands the spectrum of 
oncogenic tyrosine kinases that regulates its activity.   
 
 
Our data also indicates that activation of PKM2 controls the shift to a 
metabolic framework that is more reliant on oxidative phosphorylation and energy 
production.  This is highlighted in Figure 3.8 where activation of PKM2 had no effect 
Figure 3.12: Working model for NPM-ALK regulation of metabolism through PKM2.  The 
phosphorylation of PKM2 by NPM-ALK results in inhibition of its enzymatic activity and the 
shift toward Warburg effect.  This metabolic program generates biomass needed from 
proliferation and produces lactate as a byproduct.  Mutating the Y105 residue or using PKM2 
activating compounds, the metabolism is shift back to a “normal” metabolism which is 
driven to produce ATP and consumes O
2
 as a result.  This form of metabolism is not 
conducive for rapid proliferation or oncogenesis. 
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on cell viability under normal oxygen conditions. This suggests that oxidative 
phosphorylation is not conducive to tumor formation as seen by the reduced colony 
formation and tumor growth in xenograft studies. 
Our findings suggest that PKM2 may serve as a therapeutic target in ALCL.  
NPM-ALK is an oncogenic tyrosine kinase that activates numerous growth-
promoting signaling pathways in ALCLs.  ALCLs are aggressive lymphomas and 
although most patients respond well to aggressive chemotherapeutic agents, many 
patients experience relapses and recurrence260.  Recently developed small 
molecular inhibitors of ALK have shown promising early responses for patients with 
NPM-ALK+ ALCL.  However, a subset of patients develops resistance to kinase 
inhibitors highlighting the need to expand on therapeutic options for these patients.  
Combination therapies that target multiple signaling pathways including NPM-ALK-
mediated metabolic changes may provide additional benefit and are worth 
investigating in clinical trial settings. 
The results of our study show for the first time that NPM-ALK regulates 
cellular metabolism to increase aerobic glycolysis, decrease oxidative 
phosphorylation and enhance biosynthesis and tumorigenesis.  We identify PKM2 as 
a new substrate of NPM-ALK and provide the mechanistic rationale for the use of 





 This study identifies PKM2 as a novel substrate of NPM-ALK and defines its 
role in reprogramming cellular metabolism in ALCL cell lines.  However, recent 
studies have greatly expanded the role of PKM2 in oncogenesis beyond metabolic 
reprogramming.  Specifically, PKM2 has been shown to be necessary for 
transcriptional activation in several complexes.  PKM2 translocates to the nucleus 
upon EGFR and ERK1/2 activation and phosphorylation of S37-PKM2231,234.  Once 
inside the nucleus, PKM2 is necessary for the transactivation of transcriptional 
regulators such as β-catenin, HIF-1α, STAT3 and Oct4230-234.  The PKM2 driven 
phosphorylation of STAT3 and Histone H3 leads to increased target gene 
expression.  Interestingly, the role of PKM2 in regulating gene transcription seems to 
be mutually exclusive to its role in glycolysis.  The dimer form of PKM2 is active in 
gene transcription, while the tetramer form of PKM2 is active in PEP to pyruvate 
conversion in glycolysis. 
 An interesting future project derived from this current study will be to address 
these transcriptional roles of PKM2 in the context of NPM-ALK and ALCL.  Is the 
S37 phosphorylation and nuclear translocation of PKM2 driven by NPM-ALK 
signaling?  Is PKM2 involved in transcriptional regulation in ALCL?  How does the 
NPM-ALK regulated Y105-PKM2 phosphorylation affect the transcriptional 
regulatory role of PKM2?  STAT3, β-catenin and HIF-1α have all been implicated in 
ALCL tumorigenesis, so it is plausible that PKM2 is involved in regulating these 







NPM-ALK signals through GSK3β to promote oncogenesis 
ABSTRACT 
The mass spectrometry-based phosphoproteomic screen described in 
Chapter 2 identified GSK3β as a signaling mediator of NPM-ALK.  Using a selective 
inhibitor of ALK, we demonstrated that the tyrosine kinase activity of ALK regulates 
the serine-9 phosphorylation of GSK3β.  Expression of NPM-ALK in 293T cells led to 
an increase of pS9-GSK3β compared to kinase-defective K210R mutant NPM-ALK 
but did not affect total GSK3β levels.  Phosphorylation of pS9-GSK3β by NPM-ALK 
was mediated by the PI3K/AKT signaling pathway.  ALK inhibition resulted in 
degradation of GSK3β substrates Mcl-1, CDC25A and GYS which was recovered 
upon chemical inhibition of the proteasome (MG132).   Furthermore, the degradation 
of Mcl-1 was recoverable with inhibition of GSK3β.  ALK inhibition resulted in 
decreased glycogen stores within the cells.  Decreased cell viability under ALK 
inhibition was rescued by GSK3β inhibition.  Stable knockdown of GSK3β conferred 
resistance to the growth inhibitory effects of ALK inhibition, as seen by viability and 
colony formation assays.  pS9-GSK3β and CDC25A were selectively expressed in 
neoplastic cells of ALK+ ALCL tissue biopsies and showed a significant correlation 
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(p<0.001).  Conversely, ALK- ALCL tissue biopsies did not show significant 
correlation of pS9-GSK3β and CDC25A expression (p<0.2).  Our results 
demonstrate that NPM-ALK regulates the phosphorylation of S9-GSK3β via 
PI3K/AKT.  The subsequent inhibition of GSK3β activity results in accumulation of 
CDC25A, Mcl-1 and GYS which confers growth advantage and protection from 
apoptosis.  These findings provide support for the role of GSK3β as a mediator of 
NPM-ALK oncogenesis.  
INTRODUCTION 
Our phosphoproteomics studies (Chapter 2) also aided us in the identification 
of GSK3β as a candidate mediator of NPM-ALK signaling.  GSK3β is a 
serine/threonine kinase that is constitutively active in resting cells262,263.  Upon 
growth factor signaling, GSK3β is phosphorylated at serine-9 which inhibits its ability 
to target key substrates for proteasomal degradation.  The inhibition of GSK3β by 
serine-9 phosphorylation is the result of the amino terminal tail of the protein folding 
back on itself and pS9 residue binding to the active site.  This active site occupation 
prevents substrates from entering.  The resulting accumulation of substrates such as 
CDC25A and Mcl-1 that regulate the cell cycle and apoptosis contributes to the 
enhanced proliferative capacity of tumor cells264-267.  GSK3β was originally 
discovered through its role in glucose metabolism and insulin signaling.  Upon 
insulin receptor activation, AKT phosphorylates and inactivates GSK3β268.  Under 
resting conditions GSK3β phosphorylates and inhibits glycogen synthase (GYS) 
preventing glycogen production.  Therefore, insulin signaling removes that inhibitory 
pressure on GYS, allowing for increased glycogen production.  GSK3β also plays a 
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key role in other signaling mechanisms.  In the WNT signaling pathway, active 
GSK3β is associated with APC and Axin to form a destruction complex.  Here 
GSK3β and CK1 phosphorylate β-catenin, targeting it for proteasomal degradation.  
Upon binding of WNT to its receptor Frizzled (FZ), the destruction complex is 
disrupted and β-catenin is free to translocate to the nucleus where it is drives WNT 
target gene expression. 
Based on our phosphoproteomic studies we hypothesized that NPM-ALK 
regulates the phosphorylation of GSK3β to induce proliferative and metabolic 
phenotypes.  The objective of this study was to define the functional relationship 
between NPM-ALK and GSK3β as well as investigate the role of GSK3β in ALCL 
oncogenesis.  We showed that serine-9 phosphorylation of GSK3β is dependent on 
NPM-ALK kinase activity and the PI3K/AKT pathway.  We provided evidence that 
NPM-ALK activity results in stabilization of Mcl-1 and CDC25A through GSK3β 
inhibition which in turn enhances cell viability, proliferation and oncogenic potential.  
Furthermore, tissue biopsies of ALK+ ALCLs express pS9-GSK3β as well as 
CDC25A provided additional support for its functional significance in ALK+ ALCLs. 
 
MATERIALS AND METHODS 
Cell lines and inhibitors:  SU-DHL-1, DEL, Karpas299 and SUPM2 cells were 
cultured in RPMI 1640 + 10% fetal bovine serum (FBS).  293T cells were cultured in 
DMEM +10% FBS.  All cells were maintained in humidified incubators containing 5% 
CO2.  SU-DHL-1 cells stably expressing tetracycline inducible shRNA targeting ALK 
were generated as previously described269.  Transient transfections were done with 
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Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  Stable GSK3β knockdown SU-DHL-
1 and Karpas299 cells were generated by lentiviral transfection with MISSION 
shRNA sequence: CCGGCCCAAATGTCAAACTACCAAACTCGAGTTTGGTAGTTT 
GACATTTGGGTTTTT (Sigma-Aldrich, St. Louis, MO).  The 7-amino-1,3,4,5,-
tetrahydrobenzoazepinone derivative selective ALK inhibitor (Compound 15, 
Cephalon, Inc, Frazer, PA) was previously described270.  CAL-101 was acquired 
from Chemietek (Indianapolis, IN).  MG132 was acquired from Sigma-Aldrich (St. 
Louis, MO). GSK3 Inhibitor IX was acquired from Calbiochem (San Diego, CA).  All 
compounds were dissolved in DMSO. 
Phosphoproteomics:  See Chapter 2. 
Western Blotting and Antibodies:  Cell lysates were resolved on 10% SDS-Page and 
transferred to nitrocellulose. Antibodies used: GSK3β, pS9-GSK3β, p-ALK (Y1604), 
Mcl-1, AKT, p-AKT (S473), PARP (rabbit, 1:1000, Cell Signaling), ALK (mouse, 
1:1000, Invitrogen), CDC25A (mouse, 1:200, Santa Cruz Biotechnology). 
Glycogen Assay:  Glycogen concentrations were measured cell lysates using 
commercially available kit (BioVision, Milpitas, CA). 
WST-1, Colony Formation, Flow Cytometry: Cell proliferation and viability was 
assessed by WST-1 assay per manufacturer’s protocol (Roche Applied Science, 
Indianapolis, IN).  Cells were seeded with an initial density of 50,000 cells/ml and 
monitored by WST every day for 4 days.  Colony formation assay was performed 
with MethoCult methylcellulose-based media per manufacturer’s protocol (Stemcell 
Technologies, Vancouver, Canada).  An initial seeding density of 200 cells/ml was 
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used.  After 14 days, colonies were stained with iodonitrotetrazolium chloride (5 
mg/ml in PBS) overnight and counted.  Apoptosis and viability were assessed by 
flow cytometry following cell staining with Annexin V and propidium iodide (PI)271. 
Immunohistochemistry: Tissue samples were obtained from the archives of the 
Hematopathology Section, Department of Pathology, University of Michigan, with 
institutional approval (HUM00023256). IHC staining was conducted with the 
following antibodies: ALK (mouse, 1:100, Dako), pS9-GSK3β (rabbit, 1:50, Cell 
Signaling Technology) and CDC25A (mouse, 1:500, Abcam). 
GSK3 Interactome:  GSK3β was cloned into the pGLUE expression vector and 
coupled with a tandem affinity purification tag (TAP-tag).  Constructs were 
transfected in 293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and 
cell lysates were collected 48 hours later.  Protein extracts were incubated in 100μl 
of packed streptavidin resin (Amersham, Piscataway, NJ) at 4°C overnight.  Resin 
was washed five times and eluted with 2mM biotin.  Eluents were separated by 
SDS-PAGE.  Gel lanes were excised and cut into 16 slices.  Upon reduction (10 mM 
DTT) and alklylation (50 mM iodoacetamide) of the cysteines, proteins were 
digested overnight with sequencing grade, modified trypsin (Promega).  Resulting 
peptides were resolved on a nano-capillary reverse phase column (Picofrit column, 
New Objective) using a 1% acetic acid/acetonitrile gradient at 300 nl/min and directly 
introduced in to an ion-trap mass spectrometer (LTQ XL, ThermoFisher).  Data-
dependent MS/MS spectra on the 5 most intense ion from each full MS scan were 
collected (relative CE ~35%).  Proteins were identified by searching the data against 
Human IPI database (v 3.41, 72,254 entries) appended with decoy (reverse) 
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sequences using X!Tandem/Trans-Proteomic Pipeline (TPP) software suite272,273.  
All proteins with a ProteinProphet probability score of >0.9 (error rate <2%) were 
considered positive identifications and manually verified. 
RESULTS 
Identification of phospho-GSK3β by mass spectrometry 
Given the oncogenic role of constitutively active NPM-ALK tyrosine kinase in 
ALK+ ALCL, we hypothesized that NPM-ALK expressing cell lines would exhibit a 
phosphoproteomic signature that would reflect the signaling cascade regulated by 
the oncogene.  To gain insight into these signaling pathways and to identify novel 
regulators of NPM-ALK induced oncogenesis, we used a phosphoproteomic 
approach274 to evaluate the tyrosine phosphorylated proteins in the NPM-ALK 
expressing SUPM2 cell line.  SUPM2 cell lysates were subjected to phosphopeptide 
enrichment using phosphotyrosine specific antibodies followed by tandem mass 
spectrometry.  NPM-ALK-derived phosphotyrosine peptides in addition to numerous 
other phosphorylated proteins were identified (data not shown).  Among this list was 
an eleven-amino acid tryptic peptide corresponding to GSK3β protein 
phosphorylated at Y216 (Figure 4.1A and B).  Of note, this phosphotyrosine peptide 
has been identified in a similar study contributing to the confidence of this candidate 
protein177.  Based on the known role of GSK3β in cellular signaling262, we 
hypothesized that GSK3β may mediate the oncogenic properties of NPM-ALK.  
Since GSK3β activity is known to be regulated by growth factor signaling through 
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serine-9 phosphorylation, we hypothesized that NPM-ALK regulates the serine 




NPM-ALK regulates the serine-9 phosphorylation of GSK3β 
In order to determine whether serine phosphorylation of GSK3β is NPM-ALK 
dependent, we utilized a small molecule (CEP-26939, Compound 15) to inhibit ALK 
kinase270.  Treatment of SU-DHL-1 cells with the ALK inhibitor for 2 and 6 hours 
Figure 4.1: Identification of phosphorylated GSK3β in NPM-ALK expressing cells  (A)  SU-
DHL-1 (ALK+ ALCL) cells were subjected to PhosphoScan (Cell Signaling Technologies, 
Danvers, MA) enrichment and tandem mass spectrometry.  Representative MS/MS 
spectrum of phosphopeptide from GSK3β is shown.  Identified b and y ions are indicated.  
(B) The sequence and cleavage sites for the identified GSK3β phosphopeptide.  
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resulted in a marked decrease in the levels of phosphorylated NPM-ALK (Y1604) but 
not total NPM-ALK (Figure 4.2A).  There was marked decrease of pS9-GSK3β in 
both a dose and time dependent manner, while total GSK3β levels remained 
unaffected.  After 6 hours of 300nM CEP treatment only 34% of the serine 
phosphorylated GSK3β remained.  Three additional ALCL-derived cell lines (DEL, 
Karpas 299 and SUPM2) were treated with 300nM CEP for 6 hours (Figure 4.2B) 
and similar to the effect observed in SU-DHL-1 cells, pS9-GSK3β was consistently 
reduced by ALK inhibition in all of the cell lines.   Notably, in contrast to the marked 
decrease in ALK phosphorylation, the decrease in pS9-GSK3β was not complete. 
This may be partially explained by the existence of other kinases that phosphorylate 
GSK3β independent of NPM-ALK.  Alternatively, the time points used may not be 
representative of the maximal loss of pS9-GSK3β.  In addition, protein phosphatases 
that regulate pS9-GSK3β may be weakly active in the context of NPM-ALK.   
Similarly, 293T cells that were transiently transfected with vectors encoding the 
kinase defective mutant (K210R) showed a 76% reduction in GSK3β serine 
phosphorylation compared to those that expressed the wild-type NPM-ALK (Figure 
4.2C).  Consistent with the previous observation, there was no effect on expression 
of total GSK3β protein levels. Next, we evaluated the effect of ALK knockdown using 
stable tetracycline inducible shRNA targeting NPM-ALK in SU-DHL-1 cells269.  
Successful knockdown of NPM-ALK, which was observed after 4 days of tetracycline 
treatment, led to a marked decrease (79%) in pS9-GSK3β (Figure 4.2D), while the 
total GSK3β protein levels remained unchanged.  These data demonstrate that 






Figure 4.2: NPM-ALK regulates pS
9
-GSK3β.  (A) SU-DHL-1 cells were treated for 2 and 6 
hours with the CEP (Compound 15, Cephalon, Inc, Frazer, PA) at indicated doses in 1% FBS 
media conditions. Cell lysates were resolved on SDS-Page gels and transferred to 
nitrocellulose membranes.  Western blot analysis of GSK3β, pS
9
-GSK3β, p-ALK (Y1604) 
(rabbit, 1:1000, Cell Signaling) and ALK (mouse, 1:1000, Invitrogen) are shown.  
Densitometry measurements were conducted with WCIF ImageJ software.  (B) DEL, Karpas 
299 and SUPM2 cells treated with DMSO or 300nM CEP for 6 hours. (C) 293T cells were 
transiently transfected with NPM-ALK WT or NPM-ALK K210R and harvested 48 hours later.  
Western blot analysis of cell lysates is shown. (D) SU-DHL-1 cells were stably transfected 
with tetracycline inducible shRNA against ALK.  After 4 days of tetracycline treatment, cells 
were harvested and subjected to western blotting.  Densitometry of pS
9
-GSK3β is indicated 
as relative to control. 
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PI3K/AKT pathway mediates NPM-ALK phosphorylation of GSK3β  
Interrogation of the phosphoproteomic data identified several serine kinases 
that are known to phosphorylate GSK3β (data not shown).   These included the 
PI3K, PKC and PKA kinases.  Since the PI3K/AKT pathway is known to be activated 
by NPM-ALK as well as responsible for GSK3β serine phosphorylation275,276 we 
hypothesized that the regulation of pS9-GSK3β by NPM-ALK is mediated by 
PI3K/AKT.  We utilized a selective small molecule inhibitor against PI3K-δ (CAL-
101)277 to determine the effect of PI3K/AKT inhibition on pS9-GSK3β in SU-DHL-1 
cells.  Exposure to CAL-101 for 24 hours at increasing concentrations resulted in 
decreased phosphorylation of pS9-GSK3β and pS473-AKT in a dose dependent 
manner (Figure 4.3).  Importantly, p-ALK was not affected by CAL-101 mediated 
inhibition of PI3K/AKT.  These data show that the PI3K/AKT pathway mediates the 
serine-9 GSK3β phosphorylation by NPM-ALK.  However, this doesn’t preclude the 
possibility that other pathways active in such as WNT 278 or PLCγ279 also contribute 






pS9-GSK3β protects CDC25A and Mcl-1 from proteasomal degradation 
The serine-9 phosphorylation of GSK3β results in inhibition of its kinase 
activity280.  Since active GSK3β is known to target a variety of proteins for 
proteasomal degradation, we hypothesized that two known substrates of GSK3β, 
CDC25A and Mcl-1, would be deregulated in ALCL cells.  We evaluated the 
expression of CDC25A in SU-DHL-1 cells after inhibition of ALK at indicated time 
points following release from double thymidine block synchronization281 (Figure 
4.4A) .  ALK inhibition resulted in significant reduction of CDC25A levels in a time 
dependent manner with only 30% of the protein remaining after 8 hours.  In contrast, 
Figure 4.3:  The PI3K/AKT pathway mediates ALK induced pS
9
-GSK3β.  SU-DHL-1 cells 
treated with CAL-101 for 24 hours in 1% DMSO.  Levels of pS
9
-GSK3β, GSK3β, p-AKT, AKT, 
p-ALK, ALK and actin were determined by western blot analysis. 
137 
 
CDC25A expression remained unchanged through the entire 8 hour time period in 
the DMSO control condition.  These data suggest that NPM-ALK deregulates the 
normal cyclical expression of CDC25A and leads to stabilization and enhanced 
expression throughout the cell cycle267.  Similarly, the expression of Mcl-1 and 
CDC25A were analyzed in SU-DHL-1 cells in the presence of CEP and/or 
proteasome inhibitor (MG132) after release from synchronization using double 
thymidine block.  As shown in Figure 4.4B, inhibition of ALK resulted in significant 
down-regulation of 
Mcl-1 (47% of control) and CDC25A (14% of control) which was recoverable by 
simultaneous inhibition of the proteasome. These data suggest that NPM-ALK 
activity enhances the stability of Mcl-1 and CDC25A.  Interestingly, MG132 
treatment resulted in recovery of Mcl-1 and CDC25A levels that exceeded the 
expression in the DMSO control (120% and 358% respectively), suggesting that 






Figure 4.4: GSK3β regulates degradation of CDC25A and Mcl-1.  (A) SU-DHL-1 cells were 
synchronized by double thymidine block.  Upon release, cells were treated with DMSO or 
300nM of CEP.  Cells were lysed at indicated times following release.  (B)  SUPM2 cells were 
treated with CEP (300nM) and/or MG132 (10μM) for 6 hours. (C)  SU-DHL-1 cells were 
treated with CEP (300nM) and/or GSK3 IX (Calbiochem, San Diego, CA) (100nM) for 6 hours. 




To determine the role of GSK3β in proteasomal degradation of Mcl-1, SU-
DHL-1 cells were treated with the CEP and/or a GSK3 inhibitor (GSK3 IX) for 6 
hours.  As shown in Figure 4.4C, the decrease in Mcl-1 upon ALK inhibition was 
abrogated by GSK3 inhibition.  Thus, NPM-ALK mediated inhibition of GSK3β 
results in protection of Mcl-1 from proteasomal degradation.  These data provide 
evidence for the role of GSK3β in enhancing the stability of Mcl-1 in NPM-ALK 
expressing cells.  Since Mcl-1 is a known anti-apoptotic protein282, we asked 
whether NPM-ALK confers resistance to apoptosis via its inhibition of GSK3β.  
Western blot analyses were performed on SU-DHL-1 and SUPM2 cell lysates to 
evaluate PARP cleavage as a surrogate marker for apoptosis283.  Cells treated with 
GSK3 IX alone resulted in no change in PARP cleavage, while ALK inhibition greatly 
reduced ALK phosphorylation and increased the cleavage of PARP (Figure 4.4D).  
Interestingly, when both enzymes were inhibited, PARP cleavage was significantly 
reduced compared to the ALK inhibitor alone.  These data indicate that NPM-ALK 
leads to inhibition of GSK3β which provide protection against apoptosis.  
pS9-GSK3β regulates GYS stability and glycogen metabolism 
GSK3β is also known to phosphorylate glycogen synthase (GYS) in the 
insulin signaling pathway268.  This phosphorylation inhibits GYS and prevents the 
formation of glycogen.  In order to determine the effects of NPM-ALK signaling 
through GSK3β on GYS, ALK was inhibited in SU-DHL-1 and SUPM2 cells using 
CEP (Figure 4.5A).  Western blot analysis showed a decrease in both pS641-GYS 
and total GYS in response to ALK inhibition.  This reduction corresponds with a 
reduction in p-ALK levels and pS9-GSK3β.  Given the decrease in both pS641-GYS 
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and total GYS, it is likely that the majority of the difference is accounted for by 
changes in total protein levels.  To determine whether this decrease in GYS is 
regulated by GSK3β SU-DHL-1 cells were treated with combination of CEP, GSK3 
IX and MG132.  As shown in Figure 4.5B, ALK phosphorylation and GSK3β 
phosphorylation are decreased when CEP is present.  Inhibition of ALK results in a 
decrease in pS641-GYS levels which is recoverable upon inhibition of the 
proteasome.  This suggests that ALK protects GYS from proteasomal degradation.  
Similarly, GYS levels are most elevated when GSK3β is chemically inhibited, further 
supporting this notion.  In order to determine the effects of GYS regulation on 
cellular glycogen levels, Karpas299 and SU-DHL-1 cells were treated with CEP for 6 
hours following glycogen quantification (Figure 4.5C).  ALK inhibition resulted in a 
decrease of glycogen stores with only 32% (SD ± 0.54%, p<0.01) and 27% (SD ± 






Figure 4.5: GSK3β regulates phosphorylation and degradation of GYS.  (A)  
Immunoblots of SU-DHL-1 and SUPM2 cell lysates following 6 hours CEP 300nM 
treatment.  (B)  Immunoblots from SU-DHL-1 cell lysates treated for 6 hours with the 
indicated inhibitors.  MG132 (10μM), CEP (300nM), GSK3IX (100nM).  (C) Glycogen assay 




GSK3β mediates NPM-ALK driven oncogenesis 
 a key mediator of NPM-ALK induced 
oncogenesis, we assessed the effect of inhibitor IX on cell viability of two ALCL-
derived cell lines. An effective dose of 100nM of GSK3 IX was selected because it 
represents a concentration well above the IC50 for GSK3β 50 for 
other serine/threonine kinases284.   As expected, CEP (100nM) resulted in a 
dramatic reduction of cell viability as determined by WST-1 (4-[3-(4-iodophenyl)-2-
(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) assay (Figure 4.6A) to 
approximately 35% of control in both cell lines.  Treatment of ALCL-derived cell 
lines, SU-DHL-1 and SUPM2 with the GSK3 inhibitor IX (100nM) did not affect 
viability after 24 hours.  Notably, exposure to both compounds simultaneously (Dual) 
resulted in a viability of 55% and 47% compared to control in SU-DHL-1 and SUPM2 
cells, respectively.  This represents a significant recovery of viability compared to 
ALK inhibition (p<.01).  Importantly, Jurkat cells (ALK negative T-lymphoblastic 
leukemia) were not responsive to either GSK3 IX or CEP and there was no recovery 
in cellular viability.  To corroborate the results of ALK and GSK3β inhibition on cell 
proliferation, we carried out flow cytometry-based Annexin V and propidium iodide 
(PI) staining to quantitatively assess cell viability (Figure 4.6B).  Similar to the results 
of the WST-1 assay, inhibition of NPM-ALK resulted in a drastic reduction (80%) in 
the percent of live (Annexin V and PI negative) cells compared to the DMSO control.    
Treatment with the GSK3β inhibitor alone did not have an effect on the percentage 
of live cells. However, inhibition of both GSK3β and NPM-ALK (Dual) resulted in 
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significant increase in the percentage of live cells compared to ALK inhibition alone 
(34%).   
 
 
Figure 4.6:  pS
9
-GSK3β confers growth advantage for ALCL cells.  (A) SU-DHL-1 (ALK+ALCL), 
SUPM2 (ALK+ ALCL) and Jurkat (ALK- ALL) cells were treated with ALK inhibitor and/or 
Inhibitor IX (GSK3 inhibitor) for 24 hours followed by WST-1 assay.  (B) SU-DHL-1 cells were 
treated with indicated inhibitors (100nM) for 24 hours.  After 15 min incubation with PI 
and Annexin V, cells were subjected to flow cytometric quantification of live cells (PI 
negative and Annexin V negative).   (C) Karpas 299 cells were pre-treated with indicated 
inhibitors (100nM) for 6 hours then seeded in to methylcellulose media (MethoCult, 
Stemcell Technologies, Vancouver, Canada).  After 14 days, colonies were stained with 
iodonitrotetrazolium chloride overnight and counted. (D) After 6 hour drug treatment but 
prior to seeding into methylcellulose media, Karpas 299 cell viability was assessed by 
trypan blue staining. (*  p < 0.05, **  p < 0.01) 
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To address the role of GSK3β in oncogenic potential of ALCL cells, 
Karpas299 cells were treated with the CEP and GSK3 IX for 6 hours prior to seeding 
into methylcellulose media for colony formation.  After 14 days, colonies were 
stained and enumerated (Figure 4.6C).  While inhibition of ALK led to significant 
reduction of the number of colonies compared to control (51%), dual inhibition of 
both GSK3β and ALK caused a recovery in the number of colonies (79% compared 
to DMSO).  We verified that 6 hour pre-treatment did not affect viability prior to 
seeding into the methylcellulose media by trypan blue staining.  This showed that 
the same number of viable cells were seeded for all conditions that were evaluated 
(Figure 4.6D). 
To further evaluate the role of GSK3β in NPM-ALK mediated oncogenesis, 
stable GSK3β knockdown cell lines were created by lentiviral transfection of shRNA 
targeted against GSK3β (Figure 4.7A) in two ALCL-derived cell lines.  SU-DHL-1 
and Karpas 299 cells stably expressing scramble or shGSK3β vectors were 
subjected to WST-1 assay following treatment with the ALK inhibitor (Figure 4.7B).  
Both cell lines expressing scramble shRNA showed a decrease in viability upon ALK 
inhibition (about 60% in both cell lines, p<0.01).  In contrast, the cells with 
knockdown of GSK3β (shGSK3β) were resistant to the growth inhibitory effect of 
ALK inhibition (p<0.01).  SU-DHL-1 cells with GSK3β knockdown showed a 12% 
(SD ± 2.9%) reduction in viability following CEP treatment, while Karpas299 showed 
a 29.5% (SD ± 1.8%) reduction.  Similarly, cells expressing scramble shRNA 
displayed a 25% (SD ± 7.2%) reduction in number of colonies following ALK 
inhibition, while those with knockdown of GSK3β (shGSK3β) were resistant to ALK 
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inhibition and showed more colonies (92%, SD ± 6.7%) (Figure 4.7C).  These data 
support the hypothesis that NPM-ALK mediated phosphorylation of GSK3β 




pS9-GSK3β is expressed in ALK+ ALCL tumors 
Immunohistochemistry (IHC) was performed on 16 ALK positive ALCL (ALK+ 
ALCL) tissue biopsies and 16 ALK negative ALCL (ALK- ALCL) tissue biopsies.  
ALK+ALCL samples showed strong staining for ALK in both the cytoplasm and 
nucleus of neoplastic cells (Figure 4.8A), while ALK- ALCL samples show not 
expression of ALK (Figure 4.8E).  Fourteen of the 16 ALK+ ALCL samples showed 
Figure 4.7: GSK3β knockdown yeild resistance to ALK inhibition.  (A) Validation of GSK3β 
stable knockdown in Karpas 299 and SU-DHL-1 cells. (B) WST-1 assay after 48 hour 
treatment with 300nM ALK inhibitor in SU-DHL-1 and Karpas 299 cells with or without 
GSK3β knockdown Each ALK inhibitor condition normalized to its DMSO control. (C) 
Karpas 299 cells with or without GSK3β knockdown was subjected to methylcellulose 
colony formation assay after treatment with ALK inhibitor for 6 hours.  Colony numbers 
normalized to DMSO for each cell condition. (*  p < 0.05, **  p < 0.01) 
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strong expression of pS9-GSK3β in the neoplastic cells with weak expression in 
adjacent endothelial cells (Figure 4.8B and D).  Additionally, 13/16 ALK+ ALCL 
cases also showed expression of CDC25A highlighting the nuclear membranes of 
the neoplastic cells (Fig 4C).   Reactive lymphocytes did not express significant 
levels of pS9-GSK3β (Figure 4.8B) or CDC25A (Figure 4.8C).  Using chi squared 
distribution to test if the observed distribution is statistically different from the 
expected randomized distribution, we found that the ALK+ ALCL cases displayed a 
significant correlation of pS9-GSK3β and CDC25A expression (p < 0.001) (Fig. 
4.8D).  In contrast, only 5/16 of the ALK- ALCL cases showed expression of pS9-
GSK3β in the neoplastic cells while the infiltrating neutrophils showed strong 
expression (Figure 4.8F and H).  CDC25A expression in ALK- ALCL was present in 
11/16 cases.  Figure 4G shows a representative case of ALK- ALCL lacking 
CDC25A expression.  In contrast to the ALK+ ALCL cases, the ALK- ALCL cases 
displayed a lack of significant correlation of pS9-GSK3β and CDC25A expression 
distribution (p < 0.2) (Figure 4.8H).  Reactive tonsillar tissues demonstrated weak 
expression of pS9-GSK3β in epithelial cells and scattered interfollicular activated T-
lymphocytes (Figure 4.8I).  CDC25A expression was strongly expressed in the 
epithelial cells and in scattered interfollicular activated T-lymphocytes (Figure 4.8J).  
These findings confirm the presence of the inhibited form of GSK3β and the 
accumulation of one of its downstream substrates in human ALCL tumor samples.  
Overexpression of CDC25A transcript has been observed in various lymphomas 
including ALK+ ALCLs285, however its expression in ALCL tumor tissue samples 








-GSK3β and CDC25A are expressed in human tumors.  ALK+ ALCL tissue 
samples were obtained from the archives of the Hematopathology Section, Department of 
Pathology, University of Michigan, with institutional approval (HUM00023256). (A,B,C) 
Representative case of ALK+ ALCL.  (E,F,G) Representative case of ALK- ALCL.  (I,J)  Reactive 
tonsil.  (A,E) IHC staining for ALK (mouse, 1:100, Dako).  (B,F,I) IHC staining for pS
9
-GSK3β 
(rabbit, 1:50, Cell Signaling Technology).  (C,G,J) IHC staining for CDC25A (mouse, 1:500, 
Abcam). (D) Tabulated results for 16 ALK+ ALCL tumor samples analyzed for 
immunohistochemical staining for CDC25A and pS
9
-GSK3β.  Immunohistochemistry results 
were evaluated using parameters of staining intensity (0-3) and percentage of 
immunoreactive neoplastic cells.  Positivity was defined by 30% or more of neoplastic cells 
showing reactivity. (H) Tabulated results for 16 ALK- ALCL tumor samples analyzed for 





Phosphoproteomic analysis of pY216-GSK3β 
A retrospective analysis of the phosphoproteomic data from chapter 2 was 
conducted to identify changes in GSK3β tyrosine phosphorylation in response to 
ALK inhibition.  Table 4.1 depicts the spectral counts identified for pY216-GSK3β in 
DMSO or CEP treated conditions.  Representative replicates from three ALCL-
derived cell lines are shown.  In each case, the amount of pY216-GSK3β increases 
in response to ALK inhibition.  These data correlate well with our previous 
biochemical findings.  The tyrosine phosphorylation of GSK3β is thought to be an 
autophosphorylation site and positively correlates with its enzymatic activity286-288.  
We show that NPM-ALK induces the serine-9 phosphorylation of GSK3β and 
therefore inhibits its ability to regulate the degradation of its downstream substrates.  
The decreased GSK3β activity driven by ALK would therefore correlate with an 
increased serine phosphorylation and a decreased tyrosine phosphorylation.  Also, 
since more tyrosine phosphorylation is present after ALK inhibition, these data 








 We next wanted to expand this study to the identification of novel GSK3β 
interacting proteins.  To this aim, we pursued a mass spectrometry based GSK3β 
interactome study.  We cloned GSK3β into a pGLUE expression vector containing a 
tandem affinity purification tag (TAP-Tag) (Figure 4.9A)289.  This TAP-Tag allows for 
purification of the bait protein (GSK3β) using two independent approaches including 
streptavidin binding and calmodulin binding for the high purity of complexes and low 
background.  However, based on validation experiments we utilized only the 
streptavidin purification because of loss of bait during the tandem purification (data 
not shown).  Figure 4.9BB shows the purification of TAP-Tag-GSK3β via western 
blot analysis.  Here, the TAP-Tag vector was expressed in 293T cells and lysed after 
48 hours.  The streptavidin beads achieved high level of binding (lane 2 and 3) of the 
TAP-Tag-GSK3β protein.  While the elution was not 100% efficient (lane 4), a large 
amount of the protein was recovered in the final product (lane 5).  SDS-PAGE and 
coomassie stain of the final product is shown in Figure 4.9C.  GSK3β was present as 
a large band, while other interacting protein bands were visible.  The empty vector 





 Following in-gel digest, LC-MS/MS was used to identify proteins interacting 
with GSK3β.  Table 4.2 shows the results of GSK3β interactome.  GSK3β was the 
most abundantly identified protein in this analysis with 31 peptides identified with 
159 spectral counts.  We also identified GSK3β interaction protein (GSKIP) in the 
interactome with 2 peptides identified with 8 spectral counts.  Since GSKIP is a 
known interacting protein with GSK3β, this serves as an internal positive control for 
Figure 4.9:  GSK3 interactome.  (A)  Representation TAP-Tag vector within the pGLUE 
expression vector.  Streptavidin (streptag) and calmodulin binding affinity tags surround an 
HA tag for protein detection and protease TEV recognition site for cleavage of streptag.  (B)  
GSK3 western blot from 293T cell lysates expressing the TAP-Tag-GSK3β. (C)  Coomassie 




the analysis290.  Therefore this list of proteins represents candidate GSK3β 
interacting proteins and may have a role in NPM-ALK driven oncogenesis or a 
broader role in other GSK3β biology. 
We selected C1QBP to validate as a novel GSK3β interacting protein.  As 
shown in Figure 4.10, C1QBP interacts with TAP-Tag-GSK3β in the streptavidin pull-
down experiment.  Here, TAP-Tag-GSK3β was capable of pulling down C1QBP 
while the empty vector was not.  These data provide confidence in the interaction 
between GSK3β and C1QBP as well as the GSK3β interactome in general.  
However, further work is warranted to confirm this interaction in an endogenous 
setting and determine the functional consequence of the interaction.  C1QBP 
(complement component 1, q subcomponent binding protein) (also known as p32) 
localizes to the mitochondrial membrane and is thought to be involved in oxidative 
phosphorylation291.  Interestingly, this protein has been implicated in cancer 
metabolism as its disruption results in a shift toward aerobic glycolysis292.  The novel 
interaction between GSK3β and C1QBP could yield another link between GSK3β 
and the regulation of cancer metabolism.  This has implications in ALK signaling and 














These studies provide insight in to a novel mechanism of NPM-ALK mediated 
oncogenesis and demonstrate the utility of phosphoproteomics in the identification of 
novel kinase signaling mechanisms.  We provide evidence for the NPM-ALK 
directed serine-9 phosphorylation of GSK3β through the PI3K/AKT pathway (Figure 
4.11).  The resulting inhibition of GSK3β causes the accumulation of CDC25A, Mcl-1 
and GYS, providing increased proliferation, survival and metabolic support. 
Our work identifies a role for NPM-ALK in driving glycogen production.  It is 
known that insulin signaling increases GYS activity and glycogen production293.  
Given the overlap between insulin receptor signaling and other growth factor 
receptor signaling, it is possible that NPM-ALK employs similar mechanisms to drive 
Figure 4.10: Validation of C1QBP and GSK3 interaction.  293T cells were transfected with 
either empty vector (EV) or TAP-Tag-GSK3β (TT-GSK3).  After 48 hours the cell lysates were 
subjected to streptavidin purification.  The flow through (FT) and pull-down (PD) were 
analyzed by western blot. 
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glycogen production.  Cancer cells have a highly increased appetite for glucose as 
evident by increased glucose uptake and rapid glycolysis190.  The ability to uptake 




Figure 4.11: Model for NPM-ALK regulation of GSK3β and it downstream substrates.  
NPM-ALK regulates the inhibitory serine-9 phosphorylation of GSK3β through the 
activation of the PI3K/AKT pathway.  The inhibited GSK3 is unable to regulate the 
protein levels of CDC25A, Mcl-1 and GYS.  The accumulated downstream substrates 




NPM-ALK signaling through GSK3β provides one mechanism through which 
NPM-ALK exerts its oncogenic potential.  This was seen by the rescue in 
proliferation when both NPM-ALK and GSK3β are inhibited (4.6).  This also accounts 
for the resistance to ALK inhibition when GSK3β is knocked down (Figure 4.7).  
However, the rescue mediated by inhibition of GSK3β was not complete.  This may 
be due to the presence of several GSK3β-independent signaling pathways that are 
regulated by NPM-ALK such as JAK/STAT or ERK 294-296.  This idea is also evident 
in the observation that pS9-GSK3β was not completely abolished by ALK inhibition 
(Figure 4.2A-B), yet a dramatic decrease in cell viability was observed.  NPM-ALK 
activates many downstream signaling pathways which can all be disrupted by 
inhibiting NPM-ALK.  We can reconstitute one of these pathways through the 
chemical inhibition or knockdown of GSK3β.  However, all other pathways remain 
“off” accounting for the less than 100% recovery in proliferation and colony 
formation. 
In conclusion, our data show that NPM-ALK regulates the inhibitory serine 
phosphorylation of GSK3β in ALCL cells, providing a growth advantage and the 
maintenance of a proliferative phenotype. Our studies uncover a novel mechanism 
of NPM-ALK mediated oncogenesis.  Detailed elucidation of such deregulated 
signaling events may be exploited in the design of targeted and combinatorial 





The mass spectrometric characterization of the GSK3β interactome 
introduces numerous directions to take future projects.  Many of the proteins 
identified could have implications in GSK3β and ALK signaling.  Specifically, the 
investigation of the GSK3β-C1QBP interaction will lead to novel discoveries about 
the regulation of cancer metabolism.  C1QBP has been shown to be upregulated in 
many cancer types297-300.  Therefore, several hypotheses could be made about the 










Alterations in the ALK gene are seen in a broad spectrum of human cancers.  
Understanding how ALK and its fusion products regulate oncogenesis is a 
necessary step in the development of therapeutics against these cancers.  We 
aimed to identify novel phenotypes and signaling molecules regulated by ALK 
through the use of powerful screening approaches followed by in depth functional 
validation.  The work presented in this dissertation provides the following scientific 
contributions: 
 ALK drives global phosphoproteomic changes with many novel substrates 
identified. 
 ALK induces metabolic reprogramming to meet the biomass requirements 
for proliferation. 
 PKM2 is a novel substrate of ALK and mediates the observed metabolic 
switch. 
 PKM2 is promising new therapeutic target in ALCL. 
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 GSK3β is a novel mediator of ALK signaling and drives broad oncogenic 
phenotypes including cell cycle progression, survival, and metabolic 
alterations. 
 This study is the first of its kind to integrate phosphoproteomics and 
metabolomics for the identification of candidate metabolic regulators. 
The work in this dissertation contributes significant advances in our understanding of 
ALK induced oncogenesis.  Additionally, this work serves as a foundation for future 
studies.  The phosphoproteomic and metabolic data sets are rich with novel 
discoveries about ALK signaling and oncogenesis.  The thorough investigation of 
these candidate signaling molecules and metabolites will likely yield additional 
important discoveries.  Investigation into the non-metabolic roles of PKM2 will offer 
opportunities to link the NPM-ALK regulation of pY105-PKM2 to gene regulation.  
Finally, the GSK3β interactome provides additional avenues of research through the 
characterization of novel mediators of GSK3β signaling dependent or independent of 
ALK.  The continued investigation of ALK signaling will identify additional therapeutic 
targets that may provide options for controlling these aggressive diseases and allow 
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